
Molecular Basis of cAMP Signaling in Pancreatic β Cells

20

George G. Holz, Oleg G. Chepurny, Colin A. Leech, Woo-Jin Song,
and Mehboob A. Hussain

Contents

Introduction	566
In Vivo Actions Of cAMP-Elevating Agents In Humans	572
In Vitro Evidence That Glucose Metabolism Stimulates cAMP Production	573
Insulin Exocytosis Is Stimulated Directly By cAMP: The Role Of PKA	574
Insulin Exocytosis Is Stimulated Directly By cAMP: The Role Of Epac2	576
Contrasting Roles Of PKA And Epac2 In The Control Of GSIS	578
Restoration Of GSIS In T2DM: A Role For Ca^{2+} Influx	578
Restoration Of GSIS In T2DM: A Role For Ca^{2+} Mobilization	580
In Vivo Studies Of The cAMP: PKA Signaling Branch In β -Cells	582
In Vivo Studies Of The cAMP: Epac2A Signaling Branch In β -Cells	585
Conclusion	587
Cross-References	589
References	589

G.G. Holz (✉)

Departments of Medicine and Pharmacology, SUNY Upstate Medical University, Syracuse, NY,
USA

e-mail: holzg@upstate.edu

O.G. Chepurny • C.A. Leech

Department of Medicine, SUNY Upstate Medical University, Syracuse, NY, USA

e-mail: chepurno@upstate.edu; leechc@upstate.edu

W.-J. Song

Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA

e-mail: wsong10@jhmi.edu; jiny-song@yahoo.com

M.A. Hussain

Departments of Pediatrics, Medicine, and Biological Chemistry, Johns Hopkins University School
of Medicine, Baltimore, MD, USA

e-mail: mhussai4@jhmi.edu

Abstract

Recent advances in conditional gene targeting and cyclic nucleotide research further our understanding of how the incretin hormone GLP-1 exerts a therapeutically important action to restore pancreatic insulin secretion in patients with type 2 diabetes mellitus (T2DM). These studies demonstrate that the pancreatic β -cell GLP-1 receptor has the capacity to signal through two distinct branches of the adenosine 3',5'-cyclic monophosphate (cAMP) signal transduction network; one branch activates protein kinase A (PKA), and the second engages a cAMP-regulated guanine nucleotide exchange factor designated as Epac2. Under normal dietary conditions, specific activation of the cAMP-PKA branch in mice dramatically augments glucose-stimulated insulin secretion (GSIS). However, under conditions of diet-induced insulin resistance, cAMP-Epac2 signaling in the control of GSIS becomes prominent. This chapter provides an update on GLP-1 receptor signaling in the islets of Langerhans, with special emphasis on key molecular events that confer "plasticity" in the β -cell cAMP signal transduction network. The reader is reminded that an excellent review of β -cell cAMP signaling can also be found in the prior first edition of this book.

Keywords

Cyclic AMP • Protein kinase A • Epac2 • GLP-1 • Diabetes

Introduction

The cytosolic second messenger cAMP is a key activating signaling molecule supporting insulin exocytosis from pancreatic β -cells located in the islets of Langerhans (Holz 2004a; Leech et al. 2010a; Tengholm 2012). cAMP exerts its insulin secretagogue actions by binding to and activating either protein kinase A (PKA, a serine/threonine protein kinase) or Epac2 (a guanine nucleotide exchange factor which in turn activates Rap1 GTPase). cAMP modulates insulin exocytosis so that it potentiates glucose-stimulated insulin secretion (GSIS) from the β -cells (Holz and Habener 1992). As illustrated in Figs. 1 and 2, the downstream targets of PKA, Epac2, and glucose that are relevant to insulin secretion include proteins that control β -cell membrane excitability (ATP-sensitive K^+ channels, K_{ATP}), Ca^{2+} influx (voltage-dependent Ca^{2+} channels, VDCCs; nonselective cation channels, NSCCs), intracellular Ca^{2+} mobilization (IP_3 receptors, IP_3R ; ryanodine receptors, RYR), as well as secretory granule and SNARE complex-associated proteins that promote Ca^{2+} -dependent exocytosis of insulin (syntaxin, SNAP-25, VAMP2, RIM2, Piccolo, Munc13-1) (Seino and Shibasaki 2005; Holz et al. 2006; Kwan and Gaisano 2007; Seino et al. 2009; Vikman et al. 2009; Leech et al. 2011; Song et al. 2011, 2013; Hussain et al. 2012; Kasai et al. 2012).

cAMP biosynthesis in β -cells is catalyzed by transmembrane adenylyl cyclases (TMACs) that use ATP as a substrate in order to generate cAMP, and it is




Fig. 1 β -cell GPCR activation by GLP-1, glucagon, GIP, or PACAP results in cAMP production catalyzed by TMACs. cAMP activates Epac2 and PKA in order to potentiate glucose-stimulated insulin secretion (GSIS). Glucose sensing by the β -cell requires glucose uptake mediated by glucose transporters (*Glut*), whereas cytosolic glucokinase (*GK*) acts as the rate-limiting enzyme for oxidative glucose metabolism. A triggering pathway for GSIS involves K_{ATP} channel closure, membrane depolarization (*Depol.*), and Ca²⁺ influx that occurs in response to the increase of cytosolic ATP/ADP concentration ratio that glucose metabolism produces. Ca²⁺ triggers exocytosis of insulin, and this action of Ca²⁺ is enhanced by PKA. Activation of Epac2 facilitates glucose-dependent closure of K_{ATP} channels, thereby sensitizing β -cells to the stimulatory effect of glucose. Thus, GLP-1 is a β -cell glucose sensitizer. Note that the Ca²⁺ signal important to exocytosis is generated by Ca²⁺ entry through VDCCs or by the mobilization of Ca²⁺ from intracellular Ca²⁺ stores. Intracellular Ca²⁺ release channels (*IP₃R*, *RYR*) located on the ER are targets of PKA and Epac2, thereby allowing cAMP to facilitate glucose-dependent release of Ca²⁺ from the ER. Nonselective Ca²⁺ channels (*NSCC*) activated in response to ER Ca²⁺ mobilization generate a depolarizing inward Na⁺/Ca²⁺ current in order to increase β -cell excitability. Resultant action potential generation leads to additional Ca²⁺ influx and insulin exocytosis. These established mechanisms of “triggered” insulin secretion are reinforced by a K_{ATP} channel-independent amplification pathway. Although less well understood, it couples glucose metabolism to the recruitment of secretory granules to the plasma membrane where they undergo exocytosis in response to Ca²⁺

terminated by cyclic nucleotide phosphodiesterases (PDEs) that hydrolyze cAMP to 5'-AMP (Furman et al. 2010). Since cAMP-elevating agents have little or no insulin secretagogue action in the absence of glucose, and since insulin secretion can be stimulated by glucose in the absence of cAMP-elevating agents, it is generally accepted that the primary stimulus for insulin secretion is glucose, whereas cAMP acts to potentiate GSIS from β -cells (Henquin 2000).




Fig. 2 SNARE complex and secretory granule-associated proteins interact in order to mediate the action of cAMP to potentiate GSIS. These proteins include syntaxin and SNAP-25 located on the plasma membrane (*PM*) and VAMP2 located on the secretory granules. High concentrations of glucose promote the interaction of SNAP-25 with VAMP2, and this interaction is enhanced under conditions in which PKA and Epac2 are activated. Snapin is a substrate for PKA, and its phosphorylation on Ser-50 facilitates its interactions with SNAP-25 and Epac2. Direct binding of cAMP to Epac2 promotes its interaction with SNAP-25. When both PKA and Epac2 are activated, SNARE complex assembly is enhanced so that insulin exocytosis may occur in response to depolarization-induced entry of Ca²⁺ through VDCCs. Rim2 (Rab3-interacting molecule2), Piccolo (a Ca²⁺ sensor), and Munc (a PKA substrate) are Epac2-interacting proteins that also participate in the cAMP-dependent control of insulin secretion

Pharmacological agents that increase levels of β -cell cAMP in order to potentiate GSIS include stimulators of TMAC activity (forskolin, cholera toxin, pertussis toxin) or inhibitors of PDE activity (IBMX) (Holz et al. 2000; Pyne and Furman 2003). The incretin hormone glucagon-like peptide-1 (GLP-1) acting at the β -cell GLP-1 receptor (GLP-1R) stimulates TMACs in order to potentiate GSIS (Thorens 1992; Mojsov et al. 1987; Orskov et al. 1988; Gromada et al. 1998b; Holz 2004b), whereas neurotransmitters such as galanin and norepinephrine inhibit TMACs to inhibit insulin secretion (Sharp 1996; Straub and Sharp 2012). The hormone leptin acting via the β -cell Ob-Rb receptor stimulates PDE isoform 3B (PDE3B) in order to inhibit insulin secretion (Zhao et al. 1998; Emilsson et al. 1997; Kieffer et al. 1997; Kulkarni et al. 1997), and a targeted knockout (KO) of Ob-Rb in β -cells of mice leads to a marked enhancement of GSIS (Morioka et al. 2012).

Class II GTP-binding protein-coupled receptors (GPCRs) expressed on β -cells are coupled to cAMP production (Winzell and Ahrén 2007; Ahrén 2009; Couvineau and Laburthe 2012), and they bind GLP-1, glucagon, glucose-dependent insulinotropic peptide (GIP), and pituitary adenylyl cyclase-activating polypeptide (PACAP). The Gila monster lizard *Heloderma* is the source of GLP-1R agonist exendin-4, and its fragment exendin-(9–39) is a GLP-1R antagonist that inhibits cAMP production and insulin secretion (De Leon et al. 2008). Unexpectedly, Class II GPCRs are structurally related to CIRL (the Ca²⁺-independent receptor for α -latrotoxin), whereas GLP-1 shares structural homology with α -latrotoxin, a venom derived from the black widow spider *Latrodectus*. These findings have

prompted efforts to develop chimeric peptides that are comprised of amino acid sequences found in both GLP-1 and α -latrotoxin. For example, human islet insulin secretion is stimulated by one such peptide designated as black widow GLP-1 (Holz and Habener 1998).

GPR119 is a Class I GPCR that mediates stimulatory effects of 2-oleoyl glycerol, lysophosphatidylcholine, and fatty acid amides (e.g., oleoylethanolamide; OEA) on cAMP production and β -cell insulin secretion (Soga et al. 2005; Overton et al. 2008; Chu et al. 2007; Hansen et al. 2011). Synthetic small molecules that activate GPR119 (e.g., AR231453) are orally administrable and are currently under investigation for use in the treatment of T2DM (Jones et al. 2009; Shah and Kowalski 2010; Hansen et al. 2012). The potential usefulness of GPR119 agonists for this purpose is emphasized by the fact that they also stimulate intestinal GLP-1 release (Chu et al. 2008; Lan et al. 2009, 2012; Hansen et al. 2011).

Drug discovery efforts have yielded β -cell cAMP-elevating GLP-1R agonists such as exenatide and liraglutide that mimic the action of GLP-1 to lower levels of blood glucose in patients with T2DM (Gutniak et al. 1992; Nathan et al. 1992; Drucker and Nauck 2006; Lovshin and Drucker 2009). In contrast to endogenous GLP-1, these GLP-1R agonists are resistant to degradation by dipeptidyl peptidase-IV (DPP-IV) (Kieffer et al. 1995). Thus, they have an extended duration of action when administered by subcutaneous injection.

Orally administrable DPP-IV inhibitors such as sitagliptin and vildagliptin also exert insulin secretagogue and blood glucose-lowering actions in patients with T2DM (Drucker and Nauck 2006; Karagiannis et al. 2012). These agents delay metabolic degradation of GLP-1, thereby enabling endogenously secreted GLP-1 to more effectively raise levels of cAMP in β -cells (Dalle et al. 2013). Current drug discovery efforts seek to broaden the base of GLP-1R-targeted therapeutics by developing an orally administrable form of GLP-1 that is a conjugate of vitamin B₁₂ (Clardy-James et al. 2013). B₁₂-GLP-1 exploits the vitamin B₁₂ uptake system that utilizes intrinsic factor (IF) in order to achieve intestinal absorption of the conjugate.

Non-peptide orally administrable GLP-1R agonists may also broaden the incretin-based therapeutic armamentarium. This approach might yield GLP-1R agonists that allosterically activate the receptor by binding to sites on the receptor that are not identical to sites that bind GLP-1 (Koole et al. 2010). Further, such small molecules may be designed to activate the receptor in a manner that “biases” its signal transduction properties. Thus, GLP-1R agonists might be tailored to selectively activate either the cAMP signaling mechanism or growth factor signaling mechanisms important to β -cell function (Koole et al. 2010).

The safety profile of GLP-1R agonists and DPP-IV inhibitors is recently questioned in reports that link their use in humans to an increased incidence of pancreatitis, exocrine pancreas dysplasia, and islet α -cell hyperplasia (Butler et al. 2013; Singh et al. 2013). These findings need to be substantiated, but it is of interest that prior *in vivo* studies of rodents or *in vitro* studies of human islets demonstrate that GLP-1R agonists enhance β -cell neogenesis, proliferation, and survival (Xu et al. 1999; Turrel et al. 2001; Li et al. 2003; Farilla et al. 2003).




Fig. 3 cAMP-stimulated gene expression in β -cells results from PKA holoenzyme activation with consequent translocation of PKA catalytic subunits to the nucleus where PKA phosphorylates CREB on Ser-133. Histone acetyltransferases p300 and CBP are transcriptional co-activators that enhance binding of Ser-133-CREB to cAMP response elements (CRE) located in 5' gene promoter sequences. Ser-133-CREB binding to CREs is also enhanced by cAMP-regulated transcriptional co-activators (CRTC). At low glucose and in the absence of cAMP-elevating agents, CRTC is phosphorylated by salt-inducible kinase (SIK) to promote its association with 14-3-3 proteins, thereby sequestering CRTC in the cytoplasm. High glucose stimulates an increase of $[Ca^{2+}]_i$ that activates the phosphatase calcineurin (CN) in order to dephosphorylate CRTC, whereas cAMP-elevating agents act via PKA to inhibit SIK activity in order to slow phosphorylation of CRTC. The net effect is that dephosphorylated CRTC dissociates from 14-3-3 proteins so that it may translocate to the nucleus, bind Ser-133-CREB, and co-activate transcription. Note that CRTC is a cAMP and Ca^{2+} coincidence detector important to β -cell gene expression

In rodents, GLP-1R agonists produce an increase of β -cell mass, but it is not clear if such a potentially beneficial effect occurs in patients with T2DM (Friedrichsen et al. 2006; Song et al. 2008; Lavine and Attie 2010; Tschen et al. 2011).

When considering how GLP-1R agonists act as β -cell trophic factors, there is evidence for an insulinotropic action at the transcriptional level that is either PKA dependent (Drucker et al. 1987) or PKA independent (Skoglund et al. 2000; Chepurny et al. 2002). The PKA-dependent action of GLP-1R agonists is mediated by cAMP response elements (CREs) located in the human insulin gene (Hay et al. 2005). As illustrated in Fig. 3, CREs bind the cAMP response element-binding protein (CREB), a basic region leucine zipper transcription factor (bZIP) that is regulated by PKA and co-activators p300 and CRTC in β -cells (Altarejos and Montminy 2011; Dalle et al. 2011b). These CREs also bind bZIPs that mediate

PKA-independent actions of GLP-1R agonists, and in this regard the insulinotropic action of GLP-1 is sensitive to Ro 318220, a serine/threonine protein kinase inhibitor that inhibits MAPK-activated kinases (RSKs) and mitogen/stress-activated kinases (MSK) that serve as CREB kinases (Chepurny et al. 2002). Transcriptional activation of insulin gene expression by GLP-1 is also accompanied by GLP-1-stimulated translational biosynthesis of proinsulin (Fehmann and Habener 1992).

PKA-mediated induction of insulin receptor substrate-2 (IRS-2) expression promotes β -cell growth in response to GLP-1 (Jhala et al. 2003; Park et al. 2006), and studies of β -cell lines or neonatal β -cells indicate that PKA also mediates transcriptional induction of cyclin D1 by GLP-1 in order to stimulate proliferation (Kim et al. 2006; Friedrichsen et al. 2006). Furthermore, a proliferative action of GLP-1 results from PKA-mediated phosphorylation of β -catenin, thereby indicating that the β -cell cAMP-PKA signaling branch exhibits signal transduction cross talk with a noncanonical Wnt signaling pathway that uses the transcription factor TCF7L2 to control gene expression (Liu and Habener 2008). PKA also mediates the action of GLP-1 to promote nuclear localization of transcription factor PDX-1, thereby enhancing the differentiated state of β -cells (Wang et al. 2001). SAD-A kinase is reported to be under the control of PKA in order for cAMP to stimulate insulin secretion (Nie et al. 2013).

A surprising finding is that a truncated GLP-1 designated as GLP-1(28–36) amide stimulates cAMP production in β -cells, thereby activating the β -catenin/TCF7L2 signaling pathway (Shao et al. 2013). Furthermore, GLP-1(28–36)amide protects against β -cell glucotoxicity by improving mitochondrial function (Liu et al. 2012). GLP-1(28–36)amide is a cell-penetrating peptide that does not exert its effects by binding to the GLP-1R, but instead acts intracellularly. Thus, it is not clear how GLP-1(28–36) amide stimulates cAMP production.

Since there is evidence that the β -cell GLP-1R signals through cAMP sensor Epac2, the possibility exists that this cAMP-regulated guanine nucleotide exchange factor participates not only in the control of insulin secretion but also β -cell growth. However, recent studies demonstrate that β -cell mass is preserved in mice with a whole-body knockout (KO) of Epac2 gene expression (Song et al. 2013). Still, additional findings demonstrate a role for Epac2 in the protection of β -cells from cytotoxicity induced by reactive oxygen species (ROS) (Mukai et al. 2011). Redox control in β -cells is under the control of thioredoxin (TxN), and TxNIPs are thioredoxin-interacting proteins that downregulate the ROS buffering capacity of thioredoxin. Thus, it is significant that GLP-1 acts via Epac2 to suppress TxNIP expression in β -cells (Shao et al. 2010).

cAMP-independent actions of GLP-1 exist, and they are also of significance when considering how GLP-1 maintains β -cells in a healthy state (Holz and Chepurny 2005). Such actions include the ability of GLP-1R agonists to counteract endoplasmic reticulum stress (Yusta et al. 2006) and to signal via the GLP-1R through β -arrestin (Sonoda et al. 2008; Dalle et al. 2011a) and epidermal growth factor (EGF) receptor transactivation (Buteau et al. 2003) in order to downregulate the activities of proapoptotic protein Bad (Quoyer et al. 2010), the SirT1

deacetylase (Bastien-Dionne et al. 2011), and transcription factor FoxO1 (Buteau et al. 2006). GLP-1 also upregulates the activities of c-Src kinase (Talbot et al. 2012), phosphatidylinositol 3-kinase (PI-3-kinase) (Buteau et al. 1999), protein kinase B (PKB) (Wang et al. 2004), protein kinase c- ζ (PKC ζ) (Buteau et al. 2001), and extracellular signal-regulated protein kinases (ERK1/2) (Arnette et al. 2003). As alluded to above, it may be possible to develop allosteric GLP-1R agonists with biased signaling properties that preferentially activate these various signaling pathways.

In Vivo Actions Of cAMP-Elevating Agents In Humans

GLP-1 and GIP are released from enteroendocrine L-cells and K-cells, respectively (Kieffer and Habener 1999; Baggio and Drucker 2007; Holst 2007; McIntosh et al. 2010). These cells are located in the intestinal wall where they act as nutrient sensors such that nutrient ingestion stimulates the release of GLP-1 and GIP into the systemic circulation. During the postprandial increase of blood glucose concentration, released GLP-1 and GIP potentiate GSIS from β -cells. Thus, GLP-1 and GIP mediate the “incretin effect” whereby gut-derived signals synergize with intestinally absorbed glucose to potentiate insulin secretion (Creutzfeldt 2005). In patients with T2DM that undergo Roux-en-Y gastric bypass surgery (RYGB), an improvement of β -cell function and glucose tolerance is observed, and these beneficial effects are related to an exaggerated release of GLP-1 from L-cells (Jorgensen et al. 2013).

It is especially interesting that T2DM can be treated with GLP-1R agonists, whereas GIP receptor agonists are ineffective (Nauck et al. 1993). Why this is the case is not clear, but it is possible that in T2DM, β -cell GIP receptor expression is reduced (Lynn et al. 2001). Alternatively, the action of GIP at the β -cell may require a cofactor that is absent in T2DM. For example, xenin-25, a peptide co-secreted with GIP from K-cells, activates local enteric nervous system reflexes that enhance β -cell GIP sensitivity in healthy individuals but not in patients with T2DM (Wice et al. 2010, 2012). Dysfunctional xenin-25 action could therefore explain why GIP is not an insulin secretagogue in T2DM.

GLP-1 receptors are expressed not only on β -cells but also on vagal sensory nerve endings that innervate the intestinal wall where L-cells are located (Ahrén 2000). Thus, locally secreted GLP-1 may act via vagal-vagal reflex pathways in which afferent sensory neuron activity is transmitted to the central nervous system, with consequent efferent activity transmitted to islets by the parasympathetic autonomic nervous system (Burcelin 2010; Hayes 2012). Parasympathetic ganglia neurons release the neurotransmitter PACAP in order to stimulate cAMP production in β -cells (Ahrén 2008), so it is possible that intestinally released GLP-1 acts indirectly via neuronally released PACAP to stimulate insulin secretion. Since GLP-1 has a short half-life in the systemic circulation (<5 min in humans), and since it is secreted in close proximity to vagal sensory nerve endings located in the wall of the intestine, a circumstance may exist in which the indirect action of GLP-1 mediated by the GLP-1R on the vagus nerve overshadows the direct action of

circulating GLP-1 at the GLP-1R on β -cells. However, a different situation exists when considering the actions of DPP-IV-resistant GLP-1R agonists since these peptides have an extended duration of action in the circulation (>30 min). Studies of mice that express the GLP-1R only in the pancreas demonstrate that a direct action of GLP-1R agonists at the β -cell GLP-1R is sufficient to potentiate GSIS and to improve glucoregulation in the absence of vagal neuron stimulation (Lamont et al. 2012). Thus, it seems likely that the β -cell GLP-1R mediates a direct insulin secretagogue action of DPP-IV-resistant GLP-1R agonists in humans.

In Vitro Evidence That Glucose Metabolism Stimulates cAMP Production

Surprisingly, cAMP production is stimulated by β -cell glucose metabolism (Landa et al. 2005; Dyachok et al. 2006, 2008; Kim et al. 2008a; Idevall-Hagren et al. 2010; Tian et al. 2011), and in the 1970s it was proposed that cAMP mediates the action of glucose to stimulate insulin secretion (Charles et al. 1975). Such an effect of glucose might be a consequence of its ability to stimulate Ca^{2+} influx and to raise levels of cytosolic Ca^{2+} , thereby stimulating TMACs that are under the control of Ca^{2+} /calmodulin (Ca^{2+} /CaM) (Delmiere et al. 2003; Roger et al. 2011). Alternatively, glucose metabolism might be coupled to HCO_3^- production that activates a soluble adenylyl cyclase (sAC) in β -cells (Ramos et al. 2008; Zippen et al. 2013).

Glucose metabolism provides ATP for TMAC-catalyzed cAMP production in β -cells. Levels of ATP at low concentrations of glucose are limiting for cAMP production such that an elevation of glucose concentration leads to increased ATP availability (Takahashi et al. 1999; Kasai et al. 2002). cAMP activates PKA, and PKA-mediated phosphorylation facilitates Ca^{2+} -dependent exocytosis of insulin (Thams et al. 2005; Hatakeyama et al. 2006, 2007). As illustrated in Fig. 4, cAMP generated by glucose metabolism also activates Epac2 (Idevall-Hagren et al. 2013), but it is uncertain if glucose and GLP-1 activate identical pools of PKA and Epac2. Finally, WFS1, an endoplasmic reticulum protein, supports glucose-stimulated TMAC activity in an as-yet-to-be determined manner (Fonseca et al. 2012).

Mathematical models predict how cytosolic levels of cAMP and Ca^{2+} oscillate under conditions in which β -cells are exposed to glucose and GLP-1 (Fridlyand et al. 2007; Ni et al. 2011; Takeda et al. 2011). In the absence of GLP-1, glucose metabolism has a modest stimulatory effect on cAMP production due to the fact that it provides substrate ATP, while also providing a cytosolic Ca^{2+} signal that stimulates Ca^{2+} /CaM-regulated TMACs. Simultaneously, Ca^{2+} -regulated PDEs are activated in order to lower levels of cAMP. Under these conditions, oscillations of cAMP and Ca^{2+} occur, and these oscillations are anti-phasic such that high levels of cAMP coincide with low levels of Ca^{2+} (Landa et al. 2005). An important prediction of these mathematical models is that exposure of β -cells to GLP-1 in the presence of glucose results in a reversal of the oscillatory activity such that high levels of cAMP coincide with high levels of Ca^{2+} . This reversal is explained by the fact that TMAC activity is also stimulated by Gs proteins linked to GLP-1




Fig. 4 Glucose metabolism provides ATP for TMAC-catalyzed cAMP production, PKA activation, and Epac2A activation. Glucose metabolism also stimulates an increase of $[Ca^{2+}]_i$ that activates guanine nucleotide exchange factors for Ras GTPase (*Ras-GEF*). Activated Ras-GTP binds to the Ras-association domain of Epac2 and recruits it to the plasma membrane where it activates Rap1 GTPase. Activated Rap1-GTP then binds the Rap-association domain of PLC ϵ in order to stimulate its intrinsic catalytic activity, thereby initiating PIP $_2$ hydrolysis with consequent production of DAG and IP $_3$. DAG activates protein kinase C- ϵ (*PKC ϵ*) in order to activate CaM-KII which then phosphorylates and activates RYR located on the ER. Simultaneously, IP $_3$ activates IP $_3$ R on the ER, and Ca $^{2+}$ released from the ER acts to promote additional Ca $^{2+}$ -induced Ca $^{2+}$ release from the ER. Ca $^{2+}$ released in this manner acts as a direct trigger for insulin secretion under conditions in which PKA activity sensitizes the release mechanism to Ca $^{2+}$

receptors. Thus, TMACs act as molecular coincidence detectors for Ca $^{2+}$ /CaM and Gs in order to generate synchronous inphase oscillations of cAMP and Ca $^{2+}$ that are of importance to insulin secretion from β -cells (Holz et al. 2008b).

Insulin Exocytosis Is Stimulated Directly By cAMP: The Role Of PKA

An established literature documents the role of cAMP as a stimulator of insulin secretion, as measured in studies of isolated islets (Prentki and Matschinski 1987; Howell et al. 1994), or in live-cell imaging and patch clamp-based assays of exocytosis

occurring in single β -cells (Seino et al. 2009; Kasai et al. 2010; Dolenšek et al. 2011). The action of cAMP occurs at “late” or “distal” steps of β -cell stimulus-secretion coupling in which cAMP has a direct action to enhance secretory granule exocytosis (Ämmälä et al. 1993; Gillis and Misler 1993; Barnett et al. 1994). As illustrated in Figs. 1, 2, and 4, this action of cAMP is both PKA dependent and PKA independent (Renstrom et al. 1997), and evidence exists that the SNARE complex-associated protein snapin mediates the PKA-dependent component (Song et al. 2011), whereas Epac2 mediates the PKA-independent component (Ozaki et al. 2000; Eliasson et al. 2003). It is presently unclear whether compartmentalized cAMP signaling results in a situation in which certain Class II GPCRs preferentially couple to either the PKA-dependent or PKA-independent branches of this cAMP signaling network.

PKA-mediated phosphorylation has diverse stimulatory effects on insulin exocytosis. In one model illustrated in Fig. 5, ATP-dependent “priming” of secretory granules located within a readily releasable pool (RRP) renders them competent to undergo exocytosis. PKA then acts at a postpriming step to enhance their Ca^{2+} -dependent fusion with the plasma membrane (Takahashi et al. 1999). Although the identity of the postpriming substrate protein phosphorylated by PKA remains to be determined, this PKA activity is stimulated by glucose metabolism and is permissive for exocytosis (Hatakeyama et al. 2006, 2007). In fact, the ability of selective Epac activator 8-pCPT-2'-*O*-Me-cAMP-AM to potentiate GSIS from human islets requires concomitant permissive PKA activity (Chepurny et al. 2010).

PKA activity also renders secretory granules within the RRP more sensitive to the stimulatory action of Ca^{2+} so that they have an increased probability to undergo exocytosis in response to Ca^{2+} (Skelin and Rupnik 2011). This action of PKA is complemented by its ability to recruit a reserve pool of secretory granules from the cytoplasm to the plasma membrane so that the RRP may be refilled under conditions of sustained exocytosis (Renstrom et al. 1997). Simultaneously, PKA activity increases the number of highly Ca^{2+} -sensitive secretory granules, some of which are located outside of the RRP (Wan et al. 2004; Yang and Gillis 2004).

Another model seeks to explain how GLP-1 potentiates GSIS in a Ca^{2+} -dependent manner (Kang et al. 2003; Holz 2004b). In the absence of GLP-1, glucose metabolism stimulates the exocytosis of secretory granules located within “active zones” where microdomains of high cytosolic $[\text{Ca}^{2+}]$ form at VDCCs. When β -cells are exposed to GLP-1, PKA activity sensitizes secretory granules to the action of Ca^{2+} , thereby ensuring that exocytosis will also occur at regions of the plasma membrane located outside of active zones. This Ca^{2+} sensitization allows a new larger source of granules to undergo exocytosis. For example, PKA activity enables additional secretory granules to undergo exocytosis in response to Ca^{2+} mobilized via a mechanism of Ca^{2+} -induced Ca^{2+} release (CICR) (Holz et al. 1999; Kang and Holz 2003).

Conceivably, all of the above-summarized processes act in concert to enable GLP-1 to potentiate GSIS. However, much of what we know concerning PKA signaling in the β -cell is based on studies using cAMP analogs in order to selectively activate PKA. New studies reveal the dangers of such an approach since Epac2 can be activated by 6-Bn-cAMP-AM, an *N*6-Benzyladenine-substituted




Fig. 5 Electrophysiological studies of β -cells define a readily releasable pool (RRP) of secretory granules that are prepositioned at the plasma membrane in order to undergo exocytosis in response to Ca^{2+} (left side of illustration). In marked contrast, imaging studies using total internal reflection microscopy (TIRF) of secretory granule trafficking indicate that secretory granules located in the cytoplasm move to the plasma membrane and immediately undergo exocytosis in response to Ca^{2+} . These secretory granules are designated as “restless newcomers,” and they do not require prepositioning at the plasma membrane (right side of illustration). This mechanism of restless newcomer exocytosis is dually regulated by glucose metabolism and cAMP, and it plays a prominent role in first phase GSIS. Studies with Epac2 KO mice demonstrate that expression of Epac2 is necessary in order for cAMP to potentiate first phase restless newcomer exocytosis. Glucose metabolism may not only provide a Ca^{2+} signal for exocytosis, but it may also induce remodeling of a cortical actin barrier so that secretory granules within the cytoplasm may transit to the plasma membrane

cAMP analog that was considered to be PKA selective (G. G. Holz, unpublished studies). As summarized below, studies using a molecular approach involving gene targeting provide new evidence for a role of PKA in the control of GSIS.

Insulin Exocytosis Is Stimulated Directly By cAMP: The Role Of Epac2

Epac2 participates in the direct control of insulin exocytosis by cAMP, and this action of Epac2 may also mediate the action of GLP-1 to potentiate GSIS (Kashima et al. 2001). Live-cell imaging studies of single β -cells provide key insights into

how these effects are achieved. By imaging the movement of β -cell secretory granules in response to glucose, it is possible to demonstrate that secretory granules fuse with the plasma membrane quickly (first phase) or with a delay (second phase). Under these conditions, cAMP potentiates first phase exocytosis in an Epac2-mediated manner (Shibasaki et al. 2007). This action of Epac2 correlates with its binding to SNARE protein SNAP-25 (Vikman et al. 2009) and SNARE complex-associated proteins Rim2 and Piccolo (Ozaki et al. 2000; Fujimoto et al. 2002; Shibasaki et al. 2004). It also correlates with Epac2-mediated phosphorylation of a microtubule-associated protein (syntabulin) that influences secretory granule trafficking (Ying et al. 2012). However, Epac2 is primarily an activator of Rap1 GTPase, so it is not yet clear how these signaling events lead to a potentiation of first phase exocytosis.

Epac2 also mediates cAMP-dependent acidification of β -cell secretory granules, thereby rendering them competent to undergo fast exocytosis in response to Ca^{2+} influx through VDCCs (Eliasson et al. 2003). This action of Epac2 is specific for an immediately releasable pool (IRP) of secretory granules that undergo exocytosis during first phase GSIS. Mechanistically, the activation of Epac2 promotes granule acidification by establishing a Cl^- concentration gradient that enables entry of protons across the secretory granule membrane. Surprisingly, a KO of the SUR1 subunit of K_{ATP} channels disrupts this action of Epac2. Since SUR1 is present in the secretory granule membrane where Cl^- channels are present (Geng et al. 2003), it could be that Epac2 and SUR1 mediate an action of cAMP to control secretory granule Cl^- channel function.

There is also evidence for cAMP-dependent stimulation of Cl^- channel activity in the plasma membrane of β -cells (Kinard and Satin 1995). Opening of these Cl^- channels generates β -cell depolarization due to the fact that the reversal potential for the corresponding Cl^- current is -34 mV (Kinard and Satin 1995). This Cl^- current is activated not only by cAMP but also by the sulfonylurea glyburide. Thus, it could be that Cl^- channels present in the β -cell plasma membrane, as well as in the secretory granule membrane, are under the control of SUR1 serving in its role as an Epac2-interacting protein (Shibasaki et al. 2004). Still, it remains to be determined if and how the guanine nucleotide exchange factor activity of Epac2 leads to Rap1-dependent opening of Cl^- channels.

When considering how Rap1 might mediate a direct action of Epac2 to control exocytosis, it is significant that there is expression of a Rap1-regulated phospholipase C- ϵ (PLC ϵ) in mouse β -cells (Dzhura et al. 2010). PLC ϵ contains a Rap1-association domain, thereby allowing cAMP to act via Epac2 and Rap1 to stimulate its catalytic activity. PLC ϵ catalyzes hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP $_2$), and it links cAMP signaling to diacylglycerol (DAG) production and PKC activation (Smrcka et al. 2012). DAG formed in the plasma membrane may then bind SNARE complex-associated proteins such as Munc13-1 in order to facilitate exocytosis (Betz et al. 1998). Simultaneously, activated PKC recruited to the plasma membrane may phosphorylate SNAP-25 in order to facilitate exocytosis (Yang et al. 2007). In this regard, it is noteworthy that sulfonylureas directly stimulate β -cell exocytosis in a PKC-dependent manner (Eliasson et al. 1996).

Since sulfonylureas are reported to directly activate Epac2 (Zhang et al. 2009), an unexpected situation may exist in which Epac2, Rap1, and PLC ϵ mediate a direct stimulatory action of sulfonylureas at β -cell secretory granules.

Contrasting Roles Of PKA And Epac2 In The Control Of GSIS

Glucose metabolism in β -cells is coupled to K_{ATP} channel closure, with resultant depolarization-induced entry of Ca^{2+} through VDCCs (Henquin 2000). In healthy β -cells this Ca^{2+} entry produces an increase of $[Ca^{2+}]_i$ that stimulates insulin exocytosis, and one study using genetically engineered mice in which there is a KO of PKA regulatory subunit 1a (PKAr1a) demonstrates that enhanced PKA activity potentiates GSIS (Song et al. 2011).

Epac2 also plays a role in the control of insulin secretion. New findings demonstrate that in healthy mice fed with a normal diet, a whole-body KO of Epac2 does not disrupt GSIS, but it does impair the action of GLP-1R agonist exendin-4 to potentiate first phase GSIS, both in vitro and in vivo (Song et al. 2013). Remarkably, a different situation exists when mice are fed with a high-fat diet that induces insulin resistance. In these unhealthy mice, Epac2 ablation disrupts insulin secretion in response to glucose alone (Song et al. 2013). Thus, a role for Epac2 in the control of GSIS is measurable in a rodent model of obesity-related T2DM.

In human T2DM an unhealthy situation also exists in which there is reduced coupling of β -cell glucose metabolism to K_{ATP} channel closure so that glucose fails to fully generate the Ca^{2+} signal that triggers insulin exocytosis (Doliba et al. 2012a). This pathology might be explained by aberrant glucose sensing by β -cell glucokinase (Doliba et al. 2012b), or by defects of mitochondrial metabolism (Wiederkehr and Wollheim 2008; Mulder and Ling 2009; Patti and Corvera 2010). The pathology might also be explained by a reduced capacity of K_{ATP} channels to close in response to the increase of cytosolic ATP/ADP concentration ratio that glucose metabolism produces. With these points in mind, we propose that Epac2 activation corrects for metabolic defects in T2DM, thereby restoring the Ca^{2+} signal that triggers insulin exocytosis. Thus, we predict that in T2DM, Epac2 participates in the restoration of GSIS by GLP-1R agonists.

Restoration Of GSIS In T2DM: A Role For Ca^{2+} Influx

A loss of first phase GSIS is one of the earliest indicators of β -cell dysfunction in a prediabetic patient (Brunzell et al. 1976). However, first phase GSIS is quickly restored during intravenous infusion of GLP-1 receptor agonist exenatide to these patients (Fehse et al. 2005). Such observations indicate that β -cells of early-stage T2DM patients have sufficient quantities of insulin available for exocytosis, yet first phase GSIS is somehow disturbed. Importantly, the secretory defect occurring in β -cells of T2DM patients might not be generalized since adequate quantities of

insulin are secreted in response to sulfonylureas (Seino et al. 2011). Sulfonylureas inhibit β -cell K_{ATP} channels to produce Ca^{2+} influx, so it might be that the fundamental mechanisms of Ca^{2+} -dependent exocytosis are not disrupted in β -cells of T2DM patients. These observations lead us to hypothesize that in T2DM, the coupling of β -cell glucose metabolism to K_{ATP} channel closure is reduced so that glucose fails to generate the necessary Ca^{2+} signal that initiates insulin secretion. When GLP-1R agonists are administered, the coupling of glucose metabolism to K_{ATP} channel closure is restored so that Ca^{2+} -dependent exocytosis of insulin may occur.

Restoration of K_{ATP} channel closure by GLP-1 is measurable under experimental conditions in which β -cells are initially exposed to a glucose-free solution that depletes intracellular ATP (Holz et al. 1993). Under these conditions, transient reintroduction of glucose weakly inhibits K_{ATP} channel activity, and this action of glucose is greatly potentiated by GLP-1, thereby generating “bursts” of action potentials (Holz et al. 1993). Such a restorative action of GLP-1 might reflect its ability to stimulate β -cell glucose metabolism. Alternatively, it might reflect an ability of GLP-1 to alter the adenine nucleotide sensitivity of K_{ATP} channels so that these channels will close more efficiently in response to an increase of cytosolic ATP/ADP concentration ratio that glucose metabolism produces (Tarasov et al. 2013).

Studies of mice lacking SUR1 and Kir6.2 subunits of K_{ATP} channels provide evidence for a K_{ATP} channel-dependent action of GLP-1 to stimulate insulin secretion. In these SUR1 and Kir6.2 KO mice, GLP-1 potentiation of GSIS is absent (Nakazaki et al. 2002; Shiota et al. 2002) or reduced (Miki et al. 2005). Furthermore, in mice harboring a tyrosine-to-stop codon (Y12STOP) mutation in the gene coding for Kir6.2, K_{ATP} channel expression and GLP-1-stimulated insulin secretion are absent (Hugill et al. 2010). Important findings are also provided by a study of patients with neonatal diabetes mellitus (NDM) owing to gain-of-function mutations (C435R; R1380) in the gene coding for SUR1 (Bourron et al. 2012). These mutations lead to overactive K_{ATP} channels and a consequent reduction of GSIS. Remarkably, the administration of a GLP-1R agonist restores insulin secretion in these patients.

PKA and Epac2 mediate the action of GLP-1 to close K_{ATP} channels such that PKA reduces the stimulatory action of Mg-ADP at SUR1 (Light et al. 2002), whereas Epac2 enhances the inhibitory action of ATP at Kir6.2 (Kang et al. 2008). The net effect is that GLP-1 produces a left shift in the dose-response relationship describing how an increase of cytosolic ATP/ADP concentration ratio (x-axis) inhibits K_{ATP} channel activity (y-axis). This mechanism of K_{ATP} channel modulation underlies the ability of GLP-1 to act as a β -cell glucose sensitizer so that it can facilitate glucose metabolism-dependent depolarization of β -cells (Holz et al. 1993). Numerous studies of human, rat, and mouse β -cells demonstrate that the glucose-dependent depolarizing action of GLP-1 in β -cells is reproduced by cAMP-elevating agents such as forskolin, IBMX, and glucagon, or by membrane-permeant cAMP analogs (Henquin and Meissner 1983; Henquin et al. 1983; Henquin and Meissner 1984a, b; Eddlestone et al. 1985; Barnett et al. 1994; He et al. 1998; Gromada et al. 1998a; Fernandez and Valdeolmillos 1999;

Suga et al. 2000; Ding et al. 2001; McQuaid et al. 2006; Kang et al. 2006, 2008; Chepurmy et al. 2010; Leech et al. 2010b, 2011).

Under conditions of K_{ATP} channel closure in which β -cell depolarization initiates bursts of action potentials, there also exists an effect of GLP-1 to inhibit the delayed rectifier voltage-dependent K^+ current (MacDonald et al. 2003). This action of GLP-1 in β -cells is mediated by the PKA signaling pathway in conjunction with epidermal growth factor transactivation signaling that stimulates PI-3K and PKC ζ activities (MacDonald et al. 2003). By inhibiting the voltage-dependent K^+ current (K_v), GLP-1 prolongs the action potential duration, thereby enhancing Ca^{2+} influx through VDCCs (Yada et al. 1993).

Nonselective cation channels (NSCCs) activated by GLP-1 in β -cells provide a depolarizing inward Na^+ current that is also important to action potential generation (Holz et al. 1995; Leech and Habener 1997). These channels are dually stimulated by cAMP and Ca^{2+} , and they appear to be a subtype of Ca^{2+} -activated NSCC, although their molecular identities remain to be ascertained. New data indicate that β -cell NSCCs are activated by Epac2 (Yoshida et al. 2012; Jarrard et al. 2013). Therefore, Epac2 might mediate a stimulatory action of GLP-1 at these channels in order to promote Ca^{2+} influx.

GLP-1 might also promote Ca^{2+} influx by upregulating β -cell glucose metabolism that closes K_{ATP} channels. For example, GLP-1 is reported to signal through cAMP and Epac2 to increase β -cell glucokinase (GK) activity (Ding et al. 2011; Park et al. 2012). Since GK activity constitutes the rate-limiting step in β -cell glucose sensing, any Epac2-mediated action of GLP-1 at GK is expected to be of major physiological significance. Potentially just as important is one report that GLP-1 stimulates mitochondrial ATP production in a β -cell line (MIN6 cells) (Tsuboi et al. 2003). However, studies using human and rodent islets dispute all of these findings (Peyot et al. 2009; Doliba et al. 2012a; Song et al. 2013), leaving it unclear whether GLP-1 does in fact stimulate β -cell glucose metabolism.

Restoration Of GSIS In T2DM: A Role For Ca^{2+} Mobilization

GLP-1 and various cAMP-elevating agents such as forskolin and PACAP mobilize an intracellular source of Ca^{2+} in β -cells (Leech et al. 2011). Thus, a Ca^{2+} mobilizing action of GLP-1 is expected to become important under conditions of T2DM in which the ability of glucose metabolism to stimulate β -cell Ca^{2+} influx is impaired. Furthermore, since β -cell mitochondrial ATP production is stimulated by Ca^{2+} released from endoplasmic reticulum (ER) Ca^{2+} stores (Tsuboi et al. 2003), the ER Ca^{2+} mobilizing action of GLP-1 might lead to a restoration of ATP production in β -cells of patients with T2DM. Therefore, it is of interest to summarize what is known concerning how GLP-1 acts via cAMP, PKA, and Epac2 to mobilize Ca^{2+} in β -cells.

As illustrated in Fig. 1, the Ca^{2+} mobilizing action of GLP-1 is explained by PKA-mediated phosphorylation of IP_3 receptor (IP_3R) and ryanodine receptor (RyR) intracellular Ca^{2+} release channels located on the ER (Holz et al. 1999;

Dyachok and Gylfe 2004; Islam et al. 1998). When considering the IP_3R , the second messenger IP_3 acts as a co-agonist with Ca^{2+} to gate the opening of IP_3R , and this process is facilitated by GLP-1 in a PKA-dependent manner. Similarly, GLP-1 sensitizes RYR to the stimulatory action of Ca^{2+} in order to facilitate Ca^{2+} -induced Ca^{2+} release (CICR) from the ER. When β -cells are exposed only to glucose, resultant Ca^{2+} influx has a limited ability to promote Ca^{2+} release from the ER. However, ER Ca^{2+} release is more efficiently triggered under conditions in which β -cells are simultaneously exposed to glucose and GLP-1. These findings lead us to propose that in T2DM, there is weak Ca^{2+} influx initiated by unhealthy β -cell glucose sensing and that GLP-1 compensates for this defect by facilitating ER Ca^{2+} release, thereby restoring a cytosolic Ca^{2+} signal important to GSIS.

As illustrated in Fig. 4, an Epac2-mediated action of GLP-1 complements these PKA-dependent mechanisms of Ca^{2+} mobilization (Kang et al. 2001, 2003, 2005). It mobilizes Ca^{2+} from the ER of β -cells, and it results from Epac2-dependent activation of a Rap1-regulated PLC ϵ (Dzhura et al. 2010). Thus, PLC ϵ links GLP-1R-stimulated cAMP production to PIP_2 hydrolysis with resultant IP_3 production, IP_3R activation, and ER Ca^{2+} mobilization. Simultaneously, DAG production and PKC activation initiate a signaling cascade that culminates with Ca^{2+} /calmodulin-dependent protein kinase-II (CaM-KII)-catalyzed phosphorylation of RYR in order to facilitate CICR (Dzhura et al. 2010). Remarkably, this Epac2-mediated action of GLP-1 to control RYR is similar to that which is described for ventricular cardiomyocytes in which RYR is under the control of β_1 -adrenergic receptors (Oestreich et al. 2007, 2009). Just as intriguing, GLP-1 acts via Epac2 and PIP_2 hydrolysis in order to stimulate atrial natriuretic peptide (ANP) release from atrial cardiomyocytes (Kim et al. 2013). Thus, it appears that an evolutionarily conserved cAMP signaling “module” comprised of Epac2, Rap1, and PLC ϵ controls CICR in β -cells and cardiomyocytes, while also promoting Ca^{2+} -dependent exocytosis of secretory granules in β -cells that contain insulin and in cardiomyocytes that contain ANP.

Less well understood is the action of GLP-1 to stimulate cyclic ADP-ribose (cADP-R) and nicotinic acid adenine dinucleotide phosphate (NAADP) production in order to mobilize Ca^{2+} from the ER, endosomes, and lysosomes of β -cells (Kim et al. 2008b). Evidently, cADP-R promotes RYR-mediated CICR, whereas NAADP acts directly at 2-pore Ca^{2+} release channels (TPCs). The NAADP receptor antagonist Ned-19 reduces GSIS from mouse islets, thereby demonstrating a clear functional link between intracellular Ca^{2+} mobilization and insulin exocytosis (Naylor et al. 2009).

When considering how cAMP-dependent intracellular Ca^{2+} mobilization influences insulin secretion, there is reason to believe that Ca^{2+} released in this manner promotes the activation of NSCCs located in the plasma membrane. Since NSCCs generate a depolarizing inward Na^+ current, their activation increases β -cell excitability in order to generate bursts of action potentials, especially under conditions of high membrane resistance in which K_{ATP} channels are closed (Cha et al. 2011). The ensuing increase of $[Ca^{2+}]_i$ is then reversed by cAMP-stimulated reuptake of Ca^{2+} into the ER (Yaekura and Yada 1998). Although ER Ca^{2+} depletion that

accompanies ER Ca^{2+} release is expected to activate store-operated Ca^{2+} channels in the plasma membrane, the existence of a cAMP-regulated store-operated Ca^{2+} current (SOC) in β -cells is questioned since cAMP fails to promote association of ER Ca^{2+} sensor Stim1 with the pore-forming subunit Orai1 of store-operated Ca^{2+} channels located in the plasma membrane (Tian et al. 2012).

As illustrated in Fig. 4, remarkable findings exist concerning PLC ϵ KO mice. First, the Ca^{2+} mobilizing action of selective Epac activator 8-pCPT-2'-*O*-Me-cAMP-AM is nearly abolished in PLC ϵ KO mice (Dzhura et al. 2010). Second, islets of PLC ϵ KO mice are smaller in diameter and contain less insulin than control wild-type (WT) mice (Dzhura et al. 2011), a finding that is consistent with the established role of PLC ϵ in growth control processes in other cell types (Smrcka et al. 2012). Especially interesting are findings that 8-pCPT-2'-*O*-Me-cAMP-AM stimulates β -cell PIP_2 hydrolysis (Leech et al. 2010b; Kumar et al. 2012) but that it has a reduced capacity to potentiate GSIS from islets of PLC ϵ KO mice (Dzhura et al. 2011). Since the Ca^{2+} mobilizing action of 8-pCPT-2'-*O*-Me-cAMP-AM in WT mouse β -cells is disrupted by a Rap-GAP that inactivates Rap1 (Dzhura et al. 2010), it is clear that PLC ϵ is a downstream target of Epac2 and Rap1 for cAMP-dependent control of insulin secretion (Shibasaki et al. 2007; Kelly et al. 2008).

In Vivo Studies Of The cAMP: PKA Signaling Branch In β -Cells

Defined genetic mouse models allow detailed in vivo analyses of the GLP-1 signaling pathways in β -cells. Specifically, the cAMP-PKA and cAMP-EPAC2A signaling branches within β -cells can be individually investigated using these models. Here, we adopt a standard classification scheme for naming the multiple isoforms of PKA regulatory subunits (Taylor et al. 2008), and we also adopt terminology in which Epac2A (i.e., full-length Epac2) is the predominant isoform of Epac2 expressed in β -cells (Niimura et al. 2009).

The PKA holoenzyme consists of the catalytic subunit (PKAcs) bound to four different regulatory subunits (PKArs 1a, 1b, 2a, and 2b). Among these, PKArs1a (prkar1a) is highly expressed in pancreatic islets (Petyuk et al. 2008). To investigate the cAMP-PKA signaling branch in β -cells, it is possible to use a mouse model specifically lacking pancreatic prkar1a (Δ prkar1a) (Song et al. 2011) by interbreeding PDX1-CRE deleter mice (Gu et al. 2002) with prkar1a floxed mice (Kirschner et al. 2005). As expected, Δ prkar1a islets do not contain prkar1a, whereas PKAcs activity is increased, as reflected by increased phosphorylation of PKAcs target CREB (Song et al. 2011). Thus, Δ prkar1a mice exhibit PKA activity that is constitutively elevated in their islets. The islet and β -cell mass of Δ prkar1a and control wild-type (WT) littermates are similar, indicating that constitutively increased islet PKA activity does not increase β -cell proliferation in vivo (Song et al. 2011). Furthermore, the proliferation marker Ki67 is also similar in Δ prkar1a and WT littermates. Based on these observations, it appears that increased β -cell proliferation is not achieved after selective activation of the

cAMP-PKA signaling branch. Such findings are remarkable in view of the fact that β -cell proliferation is stimulated in WT mice during pharmacologic activation of the GLP-1R with exendin-4 (Song et al. 2008).

When examined at baseline fasting conditions, Δ prkar1a mice do not show any abnormalities in glucose homeostasis (Song et al. 2011). Baseline glucose and insulin levels are similar to those in control littermates. However, Δ prkar1a mice exhibit augmented insulin secretion, as measured in an intraperitoneal glucose tolerance test (ipGTT). GSIS is prompt and serum insulin concentrations after acute administration of glucose are eight- to tenfold higher than in littermate controls. These findings obtained with Δ prkar1a mice are similar to findings obtained using mice that are engineered to allow inducible expression of a constitutively active PKAc transgene specifically in β -cells (Kaihara et al. 2013). In these studies of transgenic mice, PKAc activity can be induced in adult mice, which are then evaluated in an ipGTT at different glucose doses. As is the case for Δ prkar1a mice, these transgenic mice with constitutively increased PKAc activity show augmented GSIS at every glucose dose administered (Kaihara et al. 2013).

Collectively, these observations obtained with two mouse models show that specific upregulation of cAMP-PKA signaling – as found during pharmacologic GLP-1R stimulation – (a) retains β -cell glucose responsiveness and (b) allows insulin secretion to be shut off at glucose levels below physiologic fasting glycaemia, and (c) at glucose levels above physiologic fasting levels, insulin secretion is dramatically augmented. Given that a whole-body KO of Epac2 does not disrupt GSIS in healthy mice (Song et al. 2013; see below), these findings suggest that in healthy β -cells, the cAMP-PKA signaling branch can in fact mediate the potentiation of endogenous incretin action. However, one caveat to this interpretation is that mouse models of constitutive PKA activity do not necessarily recapitulate compartmentalized cAMP signaling that is expected to occur in β -cells after pharmacologic GLP-1R agonist stimulation (Holz et al. 2008b). Furthermore, since these engineered mice have chronically elevated PKA activity, enhanced GSIS could reflect alterations of β -cell gene expression that are secondary to CREB activation (Dalle et al. 2011b).

It remains unclear how the cAMP-PKA signaling branch modulates glucose-stimulated Ca^{2+} handling under conditions of constitutive PKA activity. Based on findings obtained in single cell assays of β -cell depolarization, PKA should sensitize β -cells to the stimulatory action of glucose (Holz et al. 1993). Thus, the consequences of increased PKA activity need to be studied over a full range of glucose concentrations. With this limitation in mind, healthy β -cells with inducible and cell-specific transgenic PKAc overexpression do not show any appreciable change in Ca^{2+} dynamics in response to a high (i.e., saturating) concentration of glucose (Kaihara et al. 2013). In contrast, islets from Δ prkar1a mice show increased Ca^{2+} dynamics after glucose stimulation (Song et al. 2013). These divergent findings obtained using different mouse models may be explained by different experimental approaches such as nonidentical means of activating PKA, different glucose concentrations tested, and differences in the outcomes of single β -cell vs. whole islet measurements.

An important aspect of compartmentalized cAMP signaling in the β -cell is that PKA-anchoring proteins (A kinase-anchoring proteins; AKAPs) bind PKA regulatory subunits in order to control and define the subcellular location of PKA's function/activity (Welch et al. 2010). It may be concluded that subcellular anchoring of PKA is required in order for GLP-1 to stimulate insulin secretion (Lester et al. 1997; Fraser et al. 1998). Thus, pharmacologic disruption of PKA anchoring impairs cAMP-dependent potentiation of GSIS (Lester et al. 1997). Still, it should be noted that AKAPs also anchor Epac proteins within defined subcellular compartments (Hong et al. 2008; Nijholt et al. 2008). Furthermore, AKAPs can anchor protein phosphatase 2B (PP2B), PKC, and PDEs (Scott and Santana 2010). It may be concluded that the potential exists for highly coordinate β -cell cAMP signaling involving PKA, Epac2, PP2B, PKC, and PDEs.

Global disruption of AKAP150 gene expression in mice impairs the ability of these mice to respond to a glucose challenge with insulin secretion while also inhibiting the action of cAMP to potentiate GSIS (Hinke et al. 2012). Furthermore, the lack of AKAP150 impairs the functionality of L-type Ca^{2+} channels and Ca^{2+} handling in the β -cell (Hinke et al. 2012). Surprisingly, in the absence of AKAP150 there is increased insulin sensitivity, thereby improving glucose tolerance in these AKAP150 KO mice (Hinke et al. 2012). Equally surprising are findings obtained using AKAP150 knock-in mice that harbor mutations in binding motifs of AKAP150 that normally permit it to interact with PKA regulatory subunits or PP2B. These studies demonstrate that a disruption of the PP2B-binding site, but not the PKA-binding site, replicates the metabolic phenotype of the whole-body AKAP150 KO (Hinke et al. 2012). This finding confirms the importance of AKAP150 in β -cell function, albeit surprisingly pointing toward a central role for the anchoring of PP2B by AKAP150. In this regard, it is noteworthy that GSIS is accompanied by PP2B-catalyzed dephosphorylation of kinesin heavy chain (Donelan et al. 2002), a component of the microtubule-associated motor protein kinesin that plays a role in the transport of secretory granules to the plasma membrane.

MyRIP (myosin and rab-interacting protein) is an AKAP that anchors PKA to the exocyst complex, an assembly of proteins that mediates secretory granule trafficking and targeting to the plasma membrane. In rat INS-1 insulin-secreting cells, an siRNA-mediated knockdown of MyRIP disrupts exocytosis in response to glucose and forskolin, and in these cells, MyRIP interacts with the Sec6 and Sec8 components of the exocyst complex (Goehring et al. 2007). Studies further indicate a reciprocal interplay between cAMP-PKA and MyRIP. While MyRIP anchors PKA to the exocyst complex, MyRIP is also phosphorylated in response to cAMP-PKA. Phospho-MyRIP in turn associates with Myosin Va (MyoVa), a motor protein involved in the transport of secretory granules (Brozzi et al. 2012). Phosphorylation of MyRIP also leads to increased phosphorylation of the MyoVa docking-receptor Rph-3A. Collectively, these data indicate that when cAMP levels are elevated, MyRIP forms a functional protein complex with MyoVa on secretory granules in order to promote secretory granule transport. Furthermore, MyRIP facilitates PKA-mediated phosphorylation of secretory granule-associated proteins to enhance exocytosis (Brozzi et al. 2012).

The SNARE complex-associated protein snapin is an established target of PKA in neurons (Chheda et al. 2001), and snapin is expressed at high levels in β -cells, where PKA activation induces its phosphorylation at serine residue 50 (Song et al. 2011). As illustrated in Fig. 2, snapin phosphorylation facilitates interactions between the vesicle-associated SNARE protein (v-SNARE; VAMP2) and the target cell surface-associated protein (t-SNARE; SNAP-25) (Chheda et al. 2001; Song et al. 2011). Interestingly, SNAP-25 also interacts with Epac2A in β -cells (Vikman et al. 2009; Song et al. 2011). These findings suggest a scenario in which multiple cAMP-dependent signaling pathways converge to assemble a complex in which each participating protein concentrates its functional role at the site of imminent exocytosis.

Another interesting aspect of snapin biology is that when mice are rendered glucose intolerant after receiving a lipid-enriched (high-fat) diet (60 % calories from saturated fats), snapin is hyperglycosylated with *N*-acetyl-glucosamine at amino acid residue serine 50 (O-GlcNac). Activation of GLP-1R signaling reverses snapin-O-GlcNacylation at serine 50 and favors S50 phosphorylation, thereby enabling snapin to associate with SNAP-25 and Epac2A (Song et al. 2011). This finding provides a unifying molecular mechanism for β -cell dysfunction, which occurs at the level of exocytosis and is rapidly and effectively reversed by pharmacologic GLP-1R agonists.

In Vivo Studies Of The cAMP: Epac2A Signaling Branch In β -Cells

The discovery of cAMP-regulated guanine nucleotide exchange factors designated as cAMP-GEF-I and cAMP-GEF-II (now known as Epac1 and Epac2) by two independent groups (de Rooij et al. 1998; Kawasaki et al. 1998) provides an explanation for PKA-independent control of insulin secretion by cAMP (Renstrom et al. 1997; Kashima et al. 2001; Nakazaki et al. 2002; Eliasson et al. 2003; Hashiguchi et al. 2006; Kwan et al. 2007; Kelley et al. 2009; Vikman et al. 2009; Chepurny et al. 2010; Idevall-Hagren et al. 2010; Dzhura et al. 2011). Consistent with the expression of Epac2 in β -cells (Leech et al. 2000; Ozaki et al. 2000), there exist PKA-independent stimulatory actions of cAMP to raise levels of Ca^{2+} in β -cells (Bode et al. 1999; Kang et al. 2001). As illustrated in Fig. 3, the PKA-independent action of cAMP to potentiate GSIS is mediated by Epac2 and its partner Rap1.

Epac2A, the full-length form of Epac2, is the predominant isoform of Epac expressed in β -cells (Niimura et al. 2009). An assessment of the role of Epac2A in the control of GSIS can be achieved using recently developed tools including membrane-permeable Epac-selective cAMP analogs (ESCAS) that activate Epac proteins but not PKA when used at low concentrations (Vliem et al. 2008; Chepurny et al. 2009), specific small molecular Epac2 inhibitors (Tsalkova et al. 2012; Chen et al. 2013), and whole-body Epac2A KO mice (Shibasaki et al. 2007; Dzhura et al. 2010), double Epac1 and Epac2 KO mice (Yang et al. 2012), as well as floxed Epac2A mice for the cell type-specific KO of Epac1 or Epac2 (Pereira et al. 2013). Thus, there exist new strategies with which to

assess the importance of Epac2 to the control of GSIS. Initial findings indicate that β -cell mass is preserved in whole-body Epac2 KO mice, whereas a defect of glucoregulation is measurable when these mice are fed with a high-fat diet (Song et al. 2013).

The generation of a mouse model with a whole-body KO of Epac2A gene expression greatly advances our understanding of how Epac2A influences insulin secretion (Song et al. 2013). β -cells and islets from Epac2A KO mice exhibit smaller elevations of cytosolic Ca^{2+} concentration in response to GLP-1R agonist exendin-4 (Dzhura et al. 2010; Song et al. 2013), and this impairment correlates with a reduced potentiation of first phase GSIS by exendin-4 in vitro (Song et al. 2013). Furthermore, in vivo assays demonstrate a reduced insulin secretagogue action of exendin-4, as measured in Epac2A KO mice following intraperitoneal administration of both glucose and exendin-4 (Song et al. 2013). Thus, Epac2A mediates, at least in part, GLP-1R agonist action to potentiate GSIS.

Epac2A interacts with secretory granule and SNARE complex-associated proteins that are important to insulin secretion (Seino et al. 2009). Since these interactions are absent in Epac2A KO mice, the reduced insulin secretagogue action of exendin-4 in Epac2A KO mice may be explained, at least in part, by the failure of cAMP to directly stimulate secretory granule exocytosis in β -cells. As illustrated in Fig. 5, imaging studies with β -cells of Epac2 KO mice indicate that Epac2 mediates cAMP-dependent potentiation of a novel mechanism of exocytosis in which secretory granules located in the cytoplasm transit to the plasma membrane where they undergo immediate release, a process of Ca^{2+} -dependent exocytosis designated as “restless newcomer” exocytosis (Shibasaki et al. 2007). Although the molecular basis for restless newcomer exocytosis is not known, it could be that this mechanism of exocytosis requires direct interactions of Epac2 with secretory granule or SNARE complex-associated proteins. Thus, the reduced capacity of exendin-4 to potentiate first phase GSIS in islets of Epac2 KO mice may be explained not only by defective Ca^{2+} handling in the β -cell but also by the failure of cAMP to directly promote restless newcomer exocytosis.

The understanding of Epac2A function in β -cells broadened dramatically when the Seino laboratory identified Epac2A as a direct cellular target of the sulfonylurea class of blood glucose-lowering agents (Zhang et al. 2009). While Epac2A KO mice exhibit normal oral and intraperitoneal glucose tolerance at baseline, they remarkably exhibit a reduced response to sulfonylureas (Zhang et al. 2009). Thus, the sulfonylureas are proposed to function by two distinct mechanisms: (a) they bind to SUR1 in order to close β -cell K_{ATP} channels and to promote Ca^{2+} -dependent insulin secretion independently of glucose metabolism, and (b) they bind to Epac2A in order to directly potentiate GSIS.

As illustrated in Fig. 4, under conditions in which β -cells are exposed to a low concentration of glucose, sulfonylureas directly inhibit K_{ATP} channels in order to generate a Ca^{2+} signal that stimulates exocytosis of secretory granules prepositioned at the plasma membrane where they are “docked” and “primed.” When β -cells are exposed to a stimulatory concentration of glucose, it could be that sulfonylureas also act via Epac2A to enhance glucose-dependent restless newcomer exocytosis. These

considerations are of therapeutic significance in view of the finding that gliclazide is unique among sulfonylureas in that it does not activate Epac2A, but binds only to SUR1 to close K_{ATP} channels (Zhang et al. 2009). What remains to be determined is exactly how sulfonylureas activate Epac2A. Since Epac2-dependent Rap1 activation by sulfonylureas is not measurable in a solution assay using recombinant Epac2A and Rap1 (Tsalkova et al. 2011; Rehmann 2012), it could be that sulfonylureas act indirectly to activate Epac2 in living cells, as might be expected since high concentrations of sulfonylureas elevate levels of cAMP by inhibiting PDEs in islets (Goldfine et al. 1971). However, PDE inhibition may not be a factor since imaging studies of living cells indicate that sulfonylureas activate Epac2A but not Epac1 (Herbst et al. 2011).

Studies with Epac2A KO mice clarify distinctions between the functional roles of Epac2A and PKA in β -cells (Song et al. 2013). Epac2A KO mice, as compared to WT littermates, exhibit impaired adaptation of insulin secretion in response to insulin resistance induced by a short-term (1 month) high-fat content diet (60 % calories from saturated fats). In addition, when the cAMP-PKA branch is disinhibited in Δ prkar1a mice, the additional absence of Epac2A blunts the augmented GSIS, which is seen in Δ prkar1a.

Epac2A KO mice fed with a normal diet show reduced responsiveness to GLP-1R activation by exendin-4 in an in vivo assay of insulin secretion, and this is also the case for in vitro studies examining insulin secretion from isolated islets of Epac2A KO mice (Song et al. 2013). Remarkably, Epac2A KO mice also show reduced potentiation of GSIS in response to pharmacologic activation of GPR40, a GPCR for long-chain fatty acids (Song et al. 2013). This finding is unexpected because GPR40 activation potentiates GSIS in a cAMP-independent manner, one involving PLC β , PIP $_2$ hydrolysis, and Ca $^{2+}$ mobilization (Mancini and Poyntout 2013). Clearly, a better understanding of GPR40 is warranted in view of the fact that GPR40 agonists are in early phases of clinical use for the treatment of T2DM (Mancini and Poyntout 2013).

In summary, Epac2A appears to be a key molecule that is required for the β -cell to respond functionally to increased insulin resistance (as found after high-fat diet) as well as to a multitude of β -cell-targeted secretagogues (GLP-1R agonists, sulfonylureas, GPR40 activators). Thus, Epac2A selective activators may constitute a new class of blood glucose-lowering agents for pharmacological intervention in the treatment of T2DM. Future studies will also be required to examine the role of Epac2A in the pathogenesis of β -cell dysfunction in T2DM and/or the metabolic syndrome. Future studies using mouse models with cell- and tissue-specific Epac2A ablation will also be necessary to discriminate any metabolic effects of Epac2A in non- β -cells.

Conclusion

Plasticity in the β -cell cAMP signaling network is increasingly viewed as an adaptive response to metabolic demands imposed by changes in nutritional status, or in response to pathophysiological processes such as insulin resistance and

glucolipototoxicity (Hinke et al. 2004). The short-term outcomes of altered cAMP signaling include a restoration of Ca^{2+} handling and secretory granule exocytosis in experimental models of T2DM. These changes induced by cAMP occur within minutes, and they result from PKA-mediated phosphorylation of snapin accompanied by Epac2-mediated activation of Rap1 and PLC ϵ . Less well understood are long-term changes of β -cell function in response to cAMP. These changes can occur on a time scale of hours, days, weeks, or months and are explained by changes in gene expression for key transcription factors, enzymes of glucose metabolism, and mediators of insulin exocytosis. Whereas PKA predominates as a stimulus for insulin secretion in healthy β -cells, a role for Epac2 in the control of GSIS is revealed under conditions of a high-fat diet (HFD).

The HFD mouse model of T2DM is characterized by compensatory islet hyperplasia with increased β -cell mass and intact β -cell glucose sensitivity, but exaggerated insulin secretion that counters peripheral insulin resistance (Winzell and Ahrén 2004). With continued administration of the HFD, there is reduced β -cell mass, diminished β -cell glucose sensitivity, and a loss of GSIS. GLP-1R agonists correct for these defects, either by preserving β -cell mass or by restoring β -cell glucose sensitivity. Compensatory processes induced by the HFD lead to a situation in which Epac2 becomes of critical importance to GSIS, even in the absence of administered GLP-1R agonists (Song et al. 2013). Why this is the case is not clear, but it might indicate that under conditions of the HFD, glucose metabolism is coupled to cAMP production and Epac2 activation in order to stimulate insulin secretion.

Equally intriguing is the finding that GLP-1R expression is upregulated in islets of mice fed with the HFD (Ahlkvist et al. 2013) and that Epac2 expression is stimulated after treatment of T2DM donor human islets with GLP-1R agonist exendin-4 (Lupi et al. 2008). Since insulin resistance is characteristic of both T2DM and the HFD mouse model, it is possible that trophic factors such as betatrophin released from the liver circulate in response to diminished insulin action (Yi et al. 2013) in order to control the expression and/or function of the GLP-1R and Epac2 in β -cells. Alternatively, the HFD might induce epigenetic control of cAMP signaling, as recently demonstrated for Epac2 (Lee et al. 2012).

Based on studies of rodents, it is possible that in human T2DM, there is an uncoupling of β -cell glucose metabolism to cAMP production (Abdel-Halim et al. 1996; Dachicourt et al. 1996). However, in the Goto-Kakazaki (GK) rat model of T2DM, a secretory defect exists in which GSIS is downregulated despite the fact that glucose-dependent cAMP production is elevated (Dolz et al. 2011). Treatment of GK islets with GLP-1 produces an exaggerated stimulation of cAMP production, thereby restoring GSIS (Dolz et al. 2011). Since Epac2 is less sensitive to cAMP in comparison with PKA (Holz et al. 2008a), it could be that Epac2 is recruited by GLP-1 into the β -cell cAMP signaling network in order to achieve this restoration of GSIS. Importantly, such an Epac2-mediated action of GLP-1 would be conditional on basal PKA activity that supports exocytosis (Chepurny et al. 2010). Thus, a new paradigm may be evident in which β -cell stimulus-secretion coupling under the control of glucose and cAMP exhibits plasticity such

that the relative importance of PKA and Epac2 to GSIS is determined by nutritional and metabolic status. The challenge now is to relate these findings concerning mice or rats to our understanding of human T2DM, while also seeking to identify new strategies with which to manipulate the β -cell cAMP signaling network.

Acknowledgments This work was supported by American Diabetes Association Basic Science Awards to GGH (7-12-BS-077) and CAL (1-12-BS-109). National Institutes of Health funding was provided to GGH (DK069575) and MAH (DK090245, DK090816, DK084949, DK079637). GGH and OGC acknowledge the support of SUNY Upstate Medical University.

Cross-References

- ▶ [ATP-Sensitive Potassium Channels in Health and Disease](#)
- ▶ [Calcium Signaling in the Islets](#)
- ▶ [Electrical, Calcium, and Metabolic Oscillations in Pancreatic Islets](#)
- ▶ [Electrophysiology of Islet Cells](#)
- ▶ [Exocytosis in Islet \$\beta\$ -Cells](#)

References

- Abdel-Halim SM, Guenifi A, Khan A, Larsson O, Berggren PO, Ostenson CG, Efendić S (1996) Impaired coupling of glucose signal to the exocytotic machinery in diabetic GK rats: a defect ameliorated by cAMP. *Diabetes* 45:934–940
- Ahlkvist L, Brown K, Ahrén B (2013) Upregulated insulin secretion in insulin-resistant mice: evidence of increased islet GLP-1 receptor levels and GPR119-activated GLP-1 secretion. *Endocr Connect* 2:69–78
- Ahrén B (2000) Autonomic regulation of islet hormone secretion – implications for health and disease. *Diabetologia* 43:393–410
- Ahrén B (2008) Role of pituitary adenylate cyclase-activating polypeptide in the pancreatic endocrine system. *Ann N Y Acad Sci* 1144:28–35
- Ahrén B (2009) Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. *Nat Rev Drug Discov* 8:369–385
- Altarejos JY, Montminy M (2011) CREB and the CRTC co-activators: sensors for hormonal and metabolic signals. *Nat Rev Mol Cell Biol* 12:141–151
- Åmmälä C, Ashcroft FM, Rorsman P (1993) Calcium-independent potentiation of insulin release by cyclic AMP in single β -cells. *Nature* 363:356–358
- Arnette D, Gibson TB, Lawrence MC, January B, Khoo S, McGlynn K, Vanderbilt CA, Cobb MH (2003) Regulation of ERK1 and ERK2 by glucose and peptide hormones in pancreatic β cells. *J Biol Chem* 278:32517–32525
- Baggio LL, Drucker DJ (2007) Biology of incretins: GLP-1 and GIP. *Gastroenterology* 132:2131–2157
- Barnett DW, Pressel DM, Chern HT, Scharp DW, Misler S (1994) cAMP-enhancing agents “permit” stimulus-secretion coupling in canine pancreatic islet β -cells. *J Membr Biol* 138:113–120
- Bastien-Dionne PO, Valenti L, Kon N, Gu W, Buteau J (2011) Glucagon-like peptide-1 inhibits the sirtuin deacetylase SirT1 to stimulate pancreatic β -cell mass expansion. *Diabetes* 60:3217–3222

- Betz A, Ashery U, Rickmann M, Augustin I, Neher E, Südhof TC, Retting J, Brose N (1998) Munc13-1 is a presynaptic phorbol ester receptor that enhances neurotransmitter release. *Neuron* 21:123–136
- Bode HP, Moormann B, Dabew R, Göke B (1999) Glucagon-like peptide-1 elevates cytosolic calcium in pancreatic β -cells independently of protein kinase A. *Endocrinology* 140:3919–3927
- Bourron O, Chebbi F, Halbron M, Saint-Martin C, Bellanné-Chantelot C, Abed A, Charbit B, Magnan C, Lacorte JM, Hartemann A (2012) Incretin effect of glucagon-like peptide-1 receptor agonist is preserved in presence of ABCC8/SUR1 mutation in β -cell. *Diabetes Care* 35:e76
- Brozzi F, Lajus S, Diraison F, Rajatileka S, Hayward K, Regazzi R, Molnár E, Váradi A (2012) MyRIP interaction with MyoVa on secretory granules is controlled by the cAMP-PKA pathway. *Mol Biol Cell* 23:4444–4455
- Brunzell JD, Robertson RP, Lerner RL, Hazzard WR, Ensinnck JW, Biermal FL, Porte D Jr (1976) Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests. *J Clin Endocrinol Metab* 42:222–229
- Burcelin R (2010) The gut-brain axis: a major gluco regulatory player. *Diabetes Metab* 36(Suppl 3):S54–S58
- Buteau J, Roduit R, Susini S, Prentki M (1999) Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in β (INS-1)-cells. *Diabetologia* 42:856–864
- Buteau J, Foisy S, Rhodes CJ, Carpenter L, Biden TJ, Prentki M (2001) Protein kinase C ζ activation mediates glucagon-like peptide-1-induced pancreatic β -cell proliferation. *Diabetes* 50:2237–2243
- Buteau J, Foisy S, Joly E, Prentki M (2003) Glucagon-like peptide-1 induces pancreatic β -cell proliferation via transactivation of the epidermal growth factor receptor. *Diabetes* 52:124–132
- Buteau J, Spatz ML, Accili D (2006) Transcription factor FoxO1 mediates glucagon-like peptide-1 effects on pancreatic β -cell mass. *Diabetes* 55:1190–1196
- Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC (2013) Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. *Diabetes* 62:2595–2604
- Cha CY, Powell T, Noma A (2011) Analyzing electrical activities of pancreatic β cells using mathematical models. *Prog Biophys Mol Biol* 107:265–273
- Charles MA, Lawecki J, Pictet R, Grodsky GM (1975) Insulin secretion. Interrelationships of glucose, cyclic adenosine 3':5'-monophosphate, and calcium. *J Biol Chem* 250:6134–6140
- Chen H, Tsalkova T, Chepurny OG, Mei FC, Holz GG, Cheng X, Zhou J (2013) Identification and characterization of small molecules as potent and specific EPAC2 antagonists. *J Med Chem* 56:952–962
- Chepurny OG, Hussain MA, Holz GG (2002) Exendin-4 as a stimulator of rat insulin I gene promoter activity via bZIP/CRE interactions sensitive to serine/threonine protein kinase inhibitor Ro 31–8220. *Endocrinology* 143:2303–2313
- Chepurny OG, Leech CA, Kelley GG, Dzhura I, Dzhura E, Li X, Rindler MJ, Schwede F, Genieser HG, Holz GG (2009) Enhanced Rap1 activation and insulin secretagogue properties of an acetoxymethyl ester of an Epac-selective cyclic AMP analog in rat INS-1 cells: studies with 8-pCPT-2'-O-Me-cAMP-AM. *J Biol Chem* 284:10728–10736
- Chepurny OG, Kelley GG, Dzhura I, Leech CA, Roe MW, Dzhura E, Li X, Schwede F, Genieser HG, Holz GG (2010) PKA-dependent potentiation of glucose-stimulated insulin secretion by Epac activator 8-pCPT-2'-O-Me-cAMP-AM in human islets of Langerhans. *Am J Physiol Endocrinol Metab* 298:E622–E633
- Chheda MG, Ashery U, Thakur P, Rettig J, Sheng ZH (2001) Phosphorylation of snapin by PKA modulates its interaction with the SNARE complex. *Nat Cell Biol* 3:331–338

- Chu ZL, Jones RM, He H, Carroll C, Gutierrez V, Lucman A, Moloney M, Gao H, Mondala H, Bagnol D, Unett D, Liang Y, Demarest K, Semple G, Behan DP, Leonard J (2007) A role for β -cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release. *Endocrinology* 148:2601–2609
- Chu ZL, Carroll C, Alfonso J, Gutierrez V, He H, Lucman A, Pedraza M, Mondala H, Gao H, Bagnol D, Chen R, Jones RM, Behan DP, Leonard J (2008) A role for intestinal endocrine cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucagon-like peptide-1 and glucose-dependent insulinotropic peptide release. *Endocrinology* 149:2038–2047
- Clardy-James S, Chepurny OG, Leech CA, Holz GG, Doyle RP (2013) Synthesis, characterization and pharmacodynamics of vitamin-B₁₂-conjugated glucagon-like peptide-1. *ChemMedChem* 8:582–586
- Couveineau A, Laburthe M (2012) The family B1 GPCR: structural aspects and interaction with accessory proteins. *Curr Drug Targets* 13:103–115
- Creutzfeldt W (2005) The [pre]-history of the incretin concept. *Regul Pept* 128:87–91
- Dachicourt N, Serradas P, Giroix MH, Gangnerau MN, Portha B (1996) Decreased glucose-induced cAMP and insulin release in islets of diabetic rats: reversal by IBMX, glucagon, GIP. *Am J Physiol* 271:E725–E732
- Dalle S, Ravier MA, Bertrand G (2011a) Emerging roles of β -arrestin-1 in the control of the pancreatic β -cell function and mass: new therapeutic strategies and consequences for drug screening. *Cell Signal* 23:522–528
- Dalle S, Quoyer J, Varin E, Costes S (2011b) Roles and regulation of the transcription factor CREB in pancreatic β -cells. *Curr Mol Pharmacol* 4:187–195
- Dalle S, Burcelin R, Gourdy P (2013) Specific actions of GLP-1 receptor agonists and DPP4 inhibitors for the treatment of pancreatic β -cell impairments in type 2 diabetes. *Cell Signal* 25:570–579
- De Leon DD, Li C, Delson MI, Matschinsky FM, Stanley CA, Stoffers DA (2008) Exendin-(9–39) corrects fasting hypoglycemia in SUR-1^{-/-} mice by lowering cAMP in pancreatic β -cells and inhibiting insulin secretion. *J Biol Chem* 283:25786–25793
- de Rooij J, Zwartkruis FJ, Verheijen MH, Cool RH, Nijman SM, Wittinghofer A, Bos JL (1998) Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. *Nature* 396:474–477
- Delmeire D, Flamez D, Hinke SA, Cali JJ, Pipeleers D, Schuit F (2003) Type VIII adenylyl cyclase in rat β cells: coincidence signal detector/generator for glucose and GLP-1. *Diabetologia* 46:1383–1393
- Ding WG, Kitasato H, Matsuura H (2001) Involvement of calmodulin in glucagon-like peptide 1 (7–36)amide-induced inhibition of the ATP-sensitive K⁺ channel in mouse pancreatic β -cells. *Exp Physiol* 86:331–339
- Ding SY, Nkobena A, Kraft CA, Markwardt ML, Rizzo MA (2011) Glucagon-like peptide-1 stimulates post-translational activation of glucokinase in pancreatic β cells. *J Biol Chem* 286:16768–16774
- Dolenšek J, Skelin M, Rupnik MS (2011) Calcium dependencies of regulated exocytosis in different endocrine cells. *Physiol Res* 60(Suppl 1):S29–S38
- Doliba NM, Qin W NH, Liu C, Buettger CW, Sotiris J, Collins HW, Li C, Stanley CA, Wilson DF, Grimsby J, Sarabu R, Naji A, Matschinsky FM (2012a) Glucokinase activation repairs defective bioenergetics of islets of Langerhans isolated from type 2 diabetics. *Am J Physiol Endocrinol Metab* 302:E87–E102
- Doliba NM, Fenner D, Zelent B, Bass J, Sarabu R, Matschinsky FM (2012b) Repair of diverse diabetic defects of β -cells in man and mouse by pharmacological glucokinase activation. *Diabetes Obes Metab* 14(Suppl 3):109–119
- Dolz M, Movassat J, Balbé D, Le Stunff H, Giroix MH, Fradet M, Kergoat M, Portha B (2011) cAMP-secretion coupling is impaired in diabetic GK/Par rat β -cells: a defect counteracted by GLP-1. *Am J Physiol Endocrinol Metab* 301:E797–E806

- Donelan MJ, Morfini G, Julyan R, Sommers S, Hays L, Kajo H, Braud I, Easom RA, Molkentin JD, Brady ST, Rhodes CJ (2002) Ca^{2+} -dependent dephosphorylation of kinesin heavy chain on β -granules in pancreatic β -cells. Implications for regulated β -granule transport and insulin exocytosis. *J Biol Chem* 277:24232–24242
- Drucker DJ, Nauck MA (2006) The incretin system: glucagon-like peptide-1 agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. *Lancet* 368:1696–1705
- Drucker DJ, Philippe J, Mojsov S, Chick WL, Habener JF (1987) Glucagon-like peptide-1 stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. *Proc Natl Acad Sci USA* 84:3434–3438
- Dyachock O, Gylfe E (2004) Ca^{2+} -Induced Ca^{2+} release via inositol 1,4,5-trisphosphate receptors is amplified by protein kinase A and triggers exocytosis in pancreatic β -cells. *J Biol Chem* 279:45455–45461
- Dyachock O, Isakov Y, S agertorp J, Tengholm A (2006) Oscillations of cyclic AMP in hormone-stimulated insulin-secreting β -cells. *Nature* 439:349–352
- Dyachock O, Idevall-Hagren O, S agertorp J, Tian J, Wuttke A, Arriemerlou C, Akusj arvi G, Gylfe E, Tengholm A (2008) Glucose-induced cyclic AMP oscillations regulate pulsatile insulin secretion. *Cell Metab* 8:26–37
- Dzhura I, Chepurny OG, Kelley GG, Leech CA, Roe MW, Dzhura E, Afshri P, Malik S, Rindler MJ, Xu X, Lu Y, Smrcka AV, Holz GG (2010) Epac2-dependent mobilization of intracellular Ca^{2+} by glucagon-like peptide-1 receptor agonist exendin-4 is disrupted in β -cells of phospholipase C ϵ knockout mice. *J Physiol* 588:4871–4889
- Dzhura I, Chepurny OG, Leech CA, Roe MW, Dzhura E, Xu X, Lu Y, Schwede F, Genieser HG, Smrcka AV, Holz GG (2011) Phospholipase C ϵ links Epac2 activation of the potentiation of glucose-stimulated insulin secretion from mouse islets of Langerhans. *Islets* 3:121–128
- Eddlestone GT, Oldham SB, Lipson LG, Premdas FH, Beigelman PM (1985) Electrical activity, cAMP concentration, and insulin release in mouse islets of Langerhans. *Am J Physiol* 248: C145–C153
- Eliasson L, Renstr om E,  amm al a C, Berggren PO, Bertorello AM, Bokvist K, Chibalin A, Deeney JT, Flatt PR, G abel J, Gromada J, Larsson O, Lindstr om P, Rhodes CJ, Rorsman P (1996) PKC-dependent stimulation of exocytosis by sulfonylureas in pancreatic β cells. *Science* 271:813–815
- Eliasson L, Ma S, Renstr om E, Barg S, Berggren PO, Galvanovskis J, Gromada J, Jing X, Lundquist I, Salehi A, Sewing S, Rorsman P (2003) SUR1 regulates PKA-independent cAMP-induced granule priming in mouse pancreatic β -cells. *J Gen Physiol* 121:181–197
- Emilsson V, Liu YL, Cawthorne MA, Morton NM, Davenport M (1997) Expression of the functional leptin receptor mRNA in pancreatic islets and direct inhibitory action of leptin on insulin secretion. *Diabetes* 46:313–316
- Farilla L, Bulotta A, Hirshberg B, Li Calzi S, Khoury N, Noushmehr H, Bertolotto C, Di Mario U, Harlan DM, Perfetti R (2003) Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. *Endocrinology* 144:5149–5158
- Fehmann HC, Habener JF (1992) Insulinotropic hormone glucagon-like peptide-1(7–37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma β TC-1 cells. *Endocrinology* 130:159–166
- Fehse F, Trautmann M, Holst JJ, Halseth AE, Nanayakkara N, Nielsen LL, Fineman MS, Kim DD, Nauck MA (2005) Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. *J Clin Endocrinol Metabol* 90:5991–5997
- Fernandez J, Valdeolmillos M (1999) Glucose-dependent stimulatory effect of glucagon-like peptide 1(7–36) amide on the electrical activity of pancreatic β -cells recorded in vivo. *Diabetes* 48:754–757
- Fonseca SG, Urano F, Weir GC, Gromada J, Burcin M (2012) Wolfram syndrome 1 and adenylyl cyclase 8 interact at the plasma membrane to regulate insulin production and secretion. *Nat Cell Biol* 14:1105–1112

- Fraser IDC, Tavalin SJ, Lester LB, Langeberg LK, Westphal AM, Dean RA, Marrion NV, Scott JD (1998) A novel lipid-anchored A-kinase anchoring protein facilitates cAMP-responsive membrane events. *EMBO J* 17:2261–2272
- Fridlyand LE, Harbeck MC, Roe MW, Philipson LH (2007) Regulation of cAMP dynamics by Ca^{2+} and G protein-coupled receptors in the pancreatic β -cell: a computational approach. *Am J Physiol Cell Physiol* 293:C1924–C1933
- Friedrichsen BN, Neubauer N, Lee YC, Gram VK, Blume N, Petersen JS, Nielsen JH, Møldrup A (2006) Stimulation of pancreatic β -cell replication by incretin involves transcriptional induction of cyclin D1 via multiple signaling pathways. *J Endocrinol* 188:481–492
- Fujimoto K, Shibasaki T, Yokoi N, Kashima Y, Matsumoto M, Sasaki T, Tajima N, Iwanaga T, Seino S (2002) Piccolo, a Ca^{2+} sensor in pancreatic β -cells. Involvement of cAMP-GEFII. Rim2.Piccolo complex in cAMP-dependent exocytosis. *J Biol Chem* 277:50497–50502
- Furman B, Ong WK, Pyne NJ (2010) Cyclic AMP signaling in pancreatic islets. *Adv Exp Med Biol* 654:281–304
- Geng X, Li L, Watkins S, Robbins PD, Drain P (2003) The insulin secretory granule is the major site of K_{ATP} channels of the endocrine pancreas. *Diabetes* 52:767–776
- Gillis KD, Misler S (1993) Enhancers of cytosolic cAMP augment depolarization-induced exocytosis from pancreatic β -cells: evidence for effects distal to Ca^{2+} entry. *Pflugers Arch* 424:195–197
- Goehring AS, Pedroja BS, Hinke SA, Langeberg LK, Scott JD (2007) MyRIP anchors protein kinase A to the exocyst complex. *J Biol Chem* 282:33155–33167
- Goldfine ID, Perlman R, Roth J (1971) Inhibition of cyclic 3',5'-AMP phosphodiesterases in islet cells and other tissues by tolbutamide. *Nature* 234:295–297
- Gromada J, Bokvist K, Ding WG, Holst JJ, Nielsen JH, Rorsman P (1998a) Glucagon-like peptide 1(7–36) amide stimulates exocytosis in human pancreatic β -cells by both proximal and distal regulatory steps in stimulus-secretion coupling. *Diabetes* 47:57–65
- Gromada J, Holst JJ, Rorsman P (1998b) Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1. *Pflugers Arch* 435:583–594
- Gu G, Dubauskaite J, Melton DA (2002) Direct evidence for the pancreatic lineage: NGN3+ cells are islet progenitors and are distinct from duct progenitors. *Development* 129:2447–2457
- Gutniak M, Ørskov C, Holst JJ, Ahrén B, Efendić S (1992) Antidiabetic effect of glucagon-like peptide-1 (7–36) amide in normal subjects and patients with diabetes mellitus. *N Engl J Med* 326:1316–1322
- Hansen HS, Rosenkilde MM, Knop FK, Wellner N, Diep TA, Rehfeld JF, Andersen UB, Holst JJ, Hansen HS (2011) 2-Oleoyl glycerol is a GPR119 agonist and signals GLP-1 release in humans. *J Clin Endocrinol Metab* 96:E1409–E1417
- Hansen HS, Rosenkilde MM, Holst JJ, Schwartz TW (2012) GPR119 as a fat sensor. *Trends Pharmacol Sci* 33:374–381
- Hashiguchi H, Nakazaki M, Koriyama N, Fukudome M, Aso K, Tei C (2006) Cyclic AMP/cAMP-GEF pathway amplifies insulin exocytosis induced by Ca^{2+} and ATP in rat islet β -cells. *Diabetes Metab Res Rev* 22:64–71
- Hatakeyama H, Kishimoto T, Nemoto T, Kasai H, Takahashi N (2006) Rapid glucose sensing by protein kinase A for insulin exocytosis in mouse pancreatic islets. *J Physiol* 570:271–282
- Hatakeyama H, Takahashi N, Kishimoto T, Nemoto T, Kasai H (2007) Two cAMP-dependent pathways differentially regulate exocytosis of large dense-core and small vesicles in mouse β -cells. *J Physiol* 582:1087–1098
- Hay CW, Sinclair EM, Bermanno G, Durward E, Tadayyon M, Docherty K (2005) Glucagon-like peptide-1 stimulates human insulin promoter activity in part through cAMP-responsive elements that lie upstream and downstream of the transcription start site. *J Endocrinol* 186:353–365
- Hayes MR (2012) Neuronal and intracellular signaling pathways mediating GLP-1 energy balance and glycemic effects. *Physiol Behav* 106:413–416

- He LP, Mears D, Atwater I, Kitasato H (1998) Glucagon induces suppression of ATP-sensitive K⁺ channel activity through a Ca²⁺/calmodulin-dependent pathway in mouse pancreatic β -cells. *J Membr Biol* 166:237–244
- Henquin JC (2000) Triggering and amplifying pathways of regulation of insulin secretion by glucose. *Diabetes* 49:1751–1760
- Henquin JC, Meissner HP (1983) Dibutylryl cyclic AMP triggers Ca²⁺ influx and Ca²⁺-dependent electrical activity in pancreatic B cells. *Biochem Biophys Res Commun* 112:614–620
- Henquin JC, Meissner HP (1984a) Effects of theophylline and dibutylryl cyclic adenosine monophosphate on the membrane potential of mouse pancreatic β -cells. *J Physiol* 351:595–612
- Henquin JC, Meissner HP (1984b) The ionic, electrical, and secretory effects of endogenous cyclic adenosine monophosphate in mouse pancreatic B cells: studies with forskolin. *Endocrinology* 115:1125–1134
- Henquin JC, Schmeer W, Meissner HP (1983) Forskolin, an activator of adenylate cyclases, increases Ca²⁺-dependent electrical activity induced by glucose in mouse pancreatic B cells. *Endocrinology* 112:2218–2220
- Herbst KJ, Coltharp C, Amzel LM, Zhang J (2011) Direct activation of Epac by sulfonylurea is isoform selective. *Chem Biol* 18:243–251
- Hinke SA, Hellemans K, Schuit FC (2004) Plasticity of the β cell insulin secretory competence: preparing the pancreatic β cell for the next meal. *J Physiol* 558:369–380
- Hinke SA, Navedo MF, Ulman A, Whiting JL, Nygren PJ, Tian G, Jimenez-Caliani AJ, Langeberg LK, Cirulli V, Tengholm A, Dell'Acqua ML, Santana LF, Scott JD (2012) Anchored phosphatases modulate glucose homeostasis. *EMBO J* 31:3991–4004
- Holst JJ (2007) The physiology of glucagon-like peptide 1. *Physiol Rev* 87:1409–1439
- Holz GG (2004a) Epac: a new cAMP-binding protein in support of glucagon-like peptide-1 receptor-mediated signal transduction in the pancreatic β -cell. *Diabetes* 53:5–13
- Holz GG (2004b) New insights concerning the glucose-dependent insulin secretagogue action of glucagon-like peptide-1 in pancreatic β -cells. *Horm Metab Res* 36:787–794
- Holz GG, Chepurny OG (2005) Diabetes outfoxed by GLP-1? *Sci STKE* 268:pe2
- Holz GG, Habener JF (1992) Signal transduction crosstalk in the endocrine system: pancreatic β -cells and the glucose competence concept. *Trends Biochem Sci* 17:388–393
- Holz GG, Habener JF (1998) Black widow spider α -latrotoxin: a presynaptic neurotoxin that shares structural homology with the glucagon-like peptide-1 family of insulin secretagogic hormones. *Comp Biochem Physiol B Biochem Mol Biol* 121:177–184
- Holz GG 4th, Kuhlreiber WM, Habener JF (1993) Pancreatic β -cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7–37). *Nature* 361:362–365
- Holz GG, Leech CA, Habener JF (1995) Activation of a cAMP-regulated Ca²⁺-signaling pathway in pancreatic β -cells by the insulinotropic hormone glucagon-like peptide-1. *J Biol Chem* 270:17749–17757
- Holz GG, Leech CA, Heller RS, Castonguay M, Habener JF (1999) cAMP-dependent mobilization of intracellular Ca²⁺ stores by activation of ryanodine receptors in pancreatic β -cells. A Ca²⁺ signaling system stimulated by the insulinotropic hormone glucagon-like peptide-1-(7–37). *J Biol Chem* 274:14147–14156
- Holz GG, Leech CA, Habener JF (2000) Insulinotropic toxins as molecular probes for analysis of glucagon-like peptide-1 receptor-mediated signal transduction in pancreatic β -cells. *Biochimie* 82:915–926
- Holz GG, Kang G, Harbeck M, Roe MW, Chepurny OG (2006) Cell physiology of cAMP sensor Epac. *J Physiol* 577:5–15
- Holz GG, Chepurny OG, Schwede F (2008a) Epac-selective cAMP analogs: new tools with which to evaluate the signal transduction properties of cAMP-regulated guanine nucleotide exchange factors. *Cell Signal* 20:10–20

- Holz GG, Heart E, Leech CA (2008b) Synchronizing Ca^{2+} and cAMP oscillations in pancreatic β -cells: a role for glucose metabolism and GLP-1 receptors? Focus on "regulation of cAMP dynamics by Ca^{2+} and G protein-coupled receptors in the pancreatic β -cell: a computational approach". *Am J Physiol Cell Physiol* 294:C4–C6
- Hong K, Lou L, Gupta S, Ribeiro-Neto F, Altschuler DL (2008) A novel Epac-Rap-PP2A signaling module controls cAMP-dependent Akt regulation. *J Biol Chem* 283:23129–23138
- Howell SL, Jones PM, Persaud SJ (1994) Regulation of insulin secretion: the role of second messengers. *Diabetologia* 37(Suppl 2):S30–S35
- Hugill A, Shimomura K, Ashcroft FM, Cox RD (2010) A mutation in KCNJ11 causing human hyperinsulinism (Y12X) results in a glucose-intolerant phenotype in the mouse. *Diabetologia* 53:2352–2356
- Hussain MA, Stratakis C, Kirschner L (2012) Prkar1a in the regulation of the insulin secretion. *Horm Metab Res* 44:759–765
- Idevall-Hagren O, Barg S, Gylfe E, Tengholm A (2010) cAMP mediators of pulsatile insulin secretion from glucose-stimulated single β -cells. *J Biol Chem* 285:23007–23018
- Idevall-Hagren O, Jakobsson I, Xu Y, Tengholm A (2013) Spatial control of Epac2 activity by cAMP and Ca^{2+} -mediated activation of Ras in pancreatic β cells. *Sci Signal* 6:ra29
- Islam MS, Leibiger I, Leibiger B, Rossi D, Sorrentino V, Ekström TJ, Westerblad H, Andrade FH, Berggren PO (1998) In situ activation of the type 2 ryanodine receptor in pancreatic β cells requires cAMP-dependent phosphorylation. *Proc Natl Acad Sci USA* 95:6145–6160
- Jarrard RE, Wang Y, Salyer AE, Pratt EP, Soderling IM, Guerra ML, Lange AM, Broderick HJ, Hockerman GH (2013) Potentiation of sulfonylurea action by an EPAC-selective cAMP analog in INS-1 cells: comparison of tolbutamide and gliclazide and a potential role for EPAC activation of a 2-APB-sensitive Ca^{2+} influx. *Mol Pharmacol* 83:191–205
- Jhala US, Canettieri G, Screaton RA, Kulkarni RN, Krajewski S, Reed J, Walker J, Lin X, White M, Montminy M (2003) cAMP promotes pancreatic β -cell survival via CREB-mediated induction of IRS2. *Genes Dev* 17:1575–1580
- Jones RM, Leonard JN, Buzard DJ, Lehmann J (2009) GPR119 agonists for the treatment of type 2 diabetes. *Expert Opin Ther Pat* 19:1339–1359
- Jørgensen NB, Dirksen C, Bojsen-Møller KN, Jacobsen SH, Worm D, Hansen DL, Kristiansen VB, Naver L, Madsbad S, Holst JJ (2013) The exaggerated glucagon-like peptide-1 response is important for the improved β -cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes. *Diabetes* 62:3044–3052
- Kaihara KA, Dickson LM, Jacobson DA, Tamarina N, Roe MW, Philipson LH, Wicksteed B (2013) β -cell-specific protein kinase A activation enhances the efficiency of glucose control by increasing acute-phase insulin secretion. *Diabetes* 62:1527–1536
- Kang G, Holz GG (2003) Amplification of exocytosis by Ca^{2+} -induced Ca^{2+} release in INS-1 pancreatic β cells. *J Physiol* 546:175–189
- Kang G, Chepurny OG, Holz GG (2001) cAMP-regulated guanine nucleotide exchange factor II (Epac2) mediates Ca^{2+} -induced Ca^{2+} release in INS-1 pancreatic β -cells. *J Physiol* 536:375–385
- Kang G, Joseph JW, Chepurny OG, Monaco M, Wheeler MB, Bos JL, Schwede F, Genieser HG, Holz GG (2003) Epac-selective cAMP analog 8-pCPT-2'-O-Me-cAMP as a stimulus for Ca^{2+} -induced Ca^{2+} release and exocytosis in pancreatic β -cells. *J Biol Chem* 278:8279–8285
- Kang G, Chepurny OG, Rindler MJ, Collis L, Chepurny Z, Li WH, Harbeck M, Roe MW, Holz GG (2005) A cAMP and Ca^{2+} coincidence detector in support of Ca^{2+} -induced Ca^{2+} release in mouse pancreatic β cells. *J Physiol* 566:173–188
- Kang G, Chepurny OG, Malester B, Rindler MJ, Rehmann H, Bos JL, Schwede F, Coetzee WA, Holz GG (2006) cAMP sensor Epac as a determinant of ATP-sensitive potassium channel activity in human pancreatic β cells and rat INS-1 cells. *J Physiol* 573:595–609
- Kang G, Leech CA, Chepurny OG, Coetzee WA, Holz GG (2008) Role of the cAMP sensor Epac as a determinant of K_{ATP} channel ATP sensitivity in human pancreatic β cells and rat INS-1 cells. *J Physiol* 586:1307–1319

- Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A (2012) Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. *BMJ* 344:e1369
- Kasai H, Suzuki T, Liu TT, Kishimoto T, Takahashi N (2002) Fast and cAMP-sensitive mode of Ca^{2+} -dependent exocytosis in pancreatic β -cells. *Diabetes* 51(Suppl 1):S19–S24
- Kasai H, Hatakeyama H, Ohno M, Takahashi N (2010) Exocytosis in islet β -cells. *Adv Exp Med Biol* 654:305–338
- Kasai H, Takahashi N, Tokumaru H (2012) Distinct initial SNARE configurations underlying the diversity of exocytosis. *Physiol Rev* 92:1915–1964
- Kashima Y, Miki T, Shibasaki T, Ozaki N, Miyazaki M, Yano H, Seino S (2001) Critical role of cAMP-GEFII-Rim2 complex in incretin-potentiated insulin secretion. *J Biol Chem* 276:46046–46053
- Kawasaki H, Springett GM, Mochizuki N, Toki S, Nakaya M, Matsuda M, Housman DE, Graybiel AM (1998) A family of cAMP-binding proteins that directly activate Rap1. *Science* 282:2275–2279
- Kelley GG, Chepurny OG, Schwede F, Genieser HG, Leech CA, Roe MW, Li X, Dzhura I, Dzhura E, Afshari P, Holz GG (2009) Glucose-dependent potentiation of mouse islet insulin secretion by Epac activator 8-pCPT-2'-O-Me-cAMP-AM. *Islets* 1:260–265
- Kelly P, Bailey CL, Fueger PT, Newgard CB, Casey PJ, Kimple ME (2008) Rap1 promotes multiple pancreatic islet cell functions and signals through mammalian target of rapamycin complex 1 to enhance proliferation. *J Biol Chem* 285(21):15777–15785
- Kieffer TJ, Habener JF (1999) The glucagon-like peptides. *Endocr Rev* 20:876–913
- Kieffer TJ, McIntosh CH, Pederson RA (1995) Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. *Endocrinology* 136:3585–3596
- Kieffer TJ, Heller RS, Leech CA, Holz GG, Habener JF (1997) Leptin suppression of insulin secretion by activation of ATP-sensitive K^+ channels in pancreatic β -cells. *Diabetes* 46:1087–1093
- Kim MJ, Kang JH, Park YG, Ryu GR, Ko SH, Jeong IK, Koh KH, RhieDJ YSH, Hahn SJ, Kim MS, Jo YH (2006) Exendin-4 induction of cyclin D1 expression in INS-1 β -cells: involvement of cAMP-responsive element. *J Endocrinol* 188:623–633
- Kim JW, Roberts CD, Berg SA, Caicedo A, Roper SD, Chaudhari N (2008a) Imaging cyclic AMP changes in pancreatic islets of transgenic reporter mice. *PLoS One* 3:e2127
- Kim BJ, Park KH, Yim CY, Takasawa S, Okamoto H, Im MJ, Kim UH (2008b) Generation of nicotinic acid adenine dinucleotide phosphate and cyclic ADP-ribose by glucagon-like peptide-1 evokes Ca^{2+} signal that is essential for insulin secretion in mouse pancreatic islets. *Diabetes* 57:868–878
- Kim M, Platt MJ, Shibasaki T, Quaggin SE, Backx PH, Seino S, Simpson JA, Drucker DJ (2013) GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. *Nat Med* 19:567–575
- Kinard TA, Satin LS (1995) An ATP-sensitive Cl^- channel current that is activated by cell swelling, cAMP, and glyburide in insulin-secreting cells. *Diabetes* 44:1461–1466
- Kirschner LS, Kuzewitt DF, Matyakhina L, Towns WH 2nd, Carney JA, Westphal H, Stratakis CA (2005) A mouse model for the Carney complex tumor syndrome develops neoplasia in AMP-responsive tissues. *Cancer Res* 65:4506–4514
- Koole C, Wootten D, Simms J, Valant C, Sridhar R, Woodman OL, Miller LJ, Summers RJ, Christopoulos A, Sexton PM (2010) Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening. *Mol Pharmacol* 78:456–465
- Kulkarni RN, Wang ZL, Wang RM, Hurley JD, Smith DM, Ghatei MA, Withers DJ, Gardiner JV, Bailey CJ, Bloom SR (1997) Leptin rapidly suppresses insulin release from insulinoma cells, rat and human islets and, in vivo, in mice. *J Clin Invest* 100:2729–2736

- Kumar DP, Rajagopal S, Mahavadi S, Mirshahi F, Grider JR, Murthy KS, Sanyal AJ (2012) Activation of transmembrane bile acid receptor TGR5 stimulates insulin secretion in pancreatic β -cells. *Biochem Biophys Res Commun* 427:600–6005
- Kwan EP, Gaisano HY (2007) New insights into the molecular mechanisms of priming of insulin exocytosis. *Diabetes Obes Metab Suppl* 2:99–108
- Kwan EP, Gao X, LeungYM GHY (2007) Activation of exchange protein directly activated by cyclic adenosine monophosphate and protein kinase A regulate common and distinct steps in promoting plasma membrane exocytic and granule-to-granule fusion in rat islet β cells. *Pancreas* 35:e45–e54
- Lamont BJ, Li Y, Kwan E, Brown TJ, Gaisano H, Drucker DJ (2012) Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice. *J Clin Invest* 122:388–402
- Lan H, Vassileva G, Corona A, Liu L, Baker H, Golovko A, Abbondanzo SJ, Hu W, Yang S, Ning Y, Del Vecchio RA, Poulet F, Laverty M, Gustafson EL, Hedrick JA, Kowalski TJ (2009) GPR119 is required for physiological regulation glucagon-like peptide-1 secretion but not for metabolic homeostasis. *J Endocrinol* 201:219–230
- Lan H, Lin HV, Wang CF, Wright MJ, Xu S, Kang L, Juhl K, Hedrick JA, Kowalski TJ (2012) Agonists at GPR119 mediate secretion of GLP-1 from mouse enteroendocrine cells through glucose-independent pathways. *Br J Pharmacol* 165:2799–2807
- Landa LR Jr, Harbeck M, Kaihara K, Chepurny O, Kitiphongspattana K, Graf O, Nikolaev VO, Lohse MJ, Holz GG, Roe MW (2005) Interplay of Ca^{2+} and cAMP signaling in the insulin-secreting MIN6 β -cell line. *J Biol Chem* 280:31294–31302
- Lavine JA, Attie AD (2010) Gastrointestinal hormones and the regulation of β -cell mass. *Ann N Y Acad Sci* 1212:41–58
- Lee H, Jaffe AE, Feinberg JI, Tryggvadottir R, Brown S, Montano C, Aryee MJ, Irizarry RA, Herbstman J, Witter FR, Goldman LR, Feinberg AP, Fallin MD (2012) DNA methylation shows genome-wide association of NFIX, RAPGEF2 and MSRB3 with gestational age at birth. *Int J Epidemiol* 41:188–199
- Leech CA, Habener JF (1997) Insulinotropic glucagon-like peptide-1-mediated activation of non-selective cation currents in insulinoma cells is mimicked by maitotoxin. *J Biol Chem* 272:17987–17993
- Leech CA, Holz GG, Chepurny OG, Habener JF (2000) Expression of cAMP-regulated guanine nucleotide exchange factors in pancreatic β -cells. *Biochem Biophys Res Commun* 278:44–47
- Leech CA, Chepurny OG, Holz GG (2010a) Epac2-dependent Rap1 activation and the control of islet insulin secretion by glucagon-like peptide-1. *Vitam Horm* 84:279–302
- Leech CA, Dzhura I, Chepurny OG, Schwede F, Genieser HG, Holz GG (2010b) Facilitation of β -cell K_{ATP} channel sulfonylurea sensitivity by a cAMP analog selective for the cAMP-regulated guanine nucleotide exchange factor Epac. *Islets* 2:72–81
- Leech CA, Dzhura I, Chepurny OG, Kang G, Schwede F, Genieser HG, Holz GG (2011) Molecular physiology of glucagon-like peptide-1 insulin secretagogue action in pancreatic β cells. *Prog Biophys Mol Biol* 107:236–247
- Lester LB, Langeberg LK, Scott JD (1997) Anchoring of protein kinase A facilitates hormone-mediated insulin secretion. *Proc Natl Acad Sci USA* 94:14942–14947
- Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ (2003) Glucagon-like peptide-1 receptor signaling modulates β cell apoptosis. *J Biol Chem* 278:471–478
- Light PE, Manning Fox JE, Riedel MJ, Wheeler MB (2002) Glucagon-like peptide-1 inhibits pancreatic ATP-sensitive potassium channels via a protein kinase A- and ADP-dependent mechanism. *Mol Endocrinol* 16:2135–2144
- Liu Z, Habener JF (2008) Glucagon-like peptide-1 activation of TCF7L2-dependent Wnt signaling enhances pancreatic β cell proliferation. *J Biol Chem* 283:8723–8735
- Liu Z, Stanojevic V, Brindamour LJ, Habener JF (2012) GLP1-derived nonapeptide GLP1(28–36)amide protects pancreatic β -cells from glucolipototoxicity. *J Endocrinol* 213:143–154

- Lovshin JA, Drucker DJ (2009) Incretin-based therapies for type 2 diabetes mellitus. *Nat Rev Endocrinol* 5:262–269
- Lupi R, Mancarella R, Del Guerra S, Bugliani M, Del Prato S, Boggi U, Mosca F, Filipponi F, Marchetti P (2008) Effects of exendin-4 on islets from type 2 diabetes patients. *Diabetes Obes Metab* 10:515–519
- Lynn FC, Pamiir N, Ng EH, McIntosh CH, Kieffer TJ, Pederson RA (2001) Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats. *Diabetes* 50:1004–1011
- MacDonald PE, Wang X, Xia F, El-kholy W, Targonsky ED, Tsushima RG, Wheeler MB (2003) Antagonism of rat β -cell voltage-dependent K^+ currents by exendin 4 requires dual activation of the cAMP/protein kinase A and phosphatidylinositol 3-kinase signaling pathways. *J Biol Chem* 278:52446–52453
- Mancini AD, Poitout V (2013) The fatty acid receptor FFA1/GPR40 a decade later: how much we know? *Trends Endocrinol Metab* 24:398–407
- McIntosh CH, Widenmaier S, Kim SJ (2010) Pleiotropic actions of the incretin hormones. *Vitam Horm* 84:21–79
- McQuaid TS, Saleh MC, Joseph JW, Gyukhandanyan A M-FJE, MacLellan JD, Wheeler MB, Chan CB (2006) cAMP-mediated signaling normalizes glucose-stimulated insulin secretion in uncoupling protein-2 overexpressing β -cells. *J Endocrinol* 190:669–680
- Miki T, Minami K, Shinozaki H, Matsumura K, Saraya A, Ikeda H, Yamada Y, Holst JJ, Seino S (2005) Distinct effects of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 on insulin secretion and gut motility. *Diabetes* 54:1056–1063
- Mojsov S, Weir GC, Habener JF (1987) Insulinotropin: glucagon-like peptide I (7–37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. *J Clin Invest* 79:616–619
- Morioka T, Dishinger JF, Reid KR, Liew CW, Zhang T, Inaba M, Kennedy RT, Kulkarni RN (2012) Enhanced GLP-1- and sulfonylurea-induced insulin secretion in islets lacking leptin signaling. *Mol Endocrinol* 26:967–976
- Mudler H, Ling C (2009) Mitochondrial dysfunction in pancreatic β -cells in type 2 diabetes. *Mol Cell Endocrinol* 297:34–40
- Mukai E, Fujimoto S, Sato H, Oneyama C, Kominato R, Sato Y, Sasaki M, Nishi Y, Okada M, Inagaki N (2011) Exendin-4 suppresses Src activation and reactive oxygen species production in diabetic Goko-Kakizaki rat islets in an Epac-dependent manner. *Diabetes* 60:218–226
- Nakazaki M, Crane A, Hu M, Seghers V, Ullrich S, Aguilar-Bryan L, Bryan J (2002) cAMP-activated protein kinase-independent potentiation of insulin secretion by cAMP is impaired in SUR1 null islets. *Diabetes* 51:3440–3449
- Nathan DM, Schreiber E, Fogel H, Mojsov S, Habener JF (1992) Insulinotropic action of glucagonlike peptide-I-(7–37) in diabetic and nondiabetic subjects. *Diabetes Care* 15:270–276
- Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W (1993) Preserved incretin activity of glucagon-like peptide 1 [7–36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. *J Clin Invest* 91:301–307
- Naylor E, Arredouani A, Vasudevan SR, Lewis AM, Parkesh R, Mizote A, Rosen D, Thomas JM, Izumi M, Ganesan A, Galione A, Churchill GC (2009) Identification of a chemical probe for NAADP by virtual screening. *Nat Chem Biol* 5:220–226
- Ni Q, Ganesan A, Aye-Han NN, Gao X, Allen MD, Levchenko A, Zhang J (2011) Signaling diversity of PKA achieved via a Ca^{2+} -cAMP-PKA oscillatory circuit. *Nat Chem Biol* 7:34–40
- Nie J, Lilley BN, Pan YA, Faruque O, Liu X, Zhang W, Sanes JR, Han X, Shi Y (2013) SAD-A kinase enhances insulin secretion as a downstream target of GLP-1 signaling in pancreatic β -cells. *Mol Cell Biol* 13:2527–2534
- Niimura M, Miki T ST, Fujimoto W, Iwanaga T, Seino S (2009) Critical role of the N-terminal cyclic AMP-binding domain of Epac2 in its subcellular localization and function. *J Cell Physiol* 219:652–658

- Nijholt IM, Dolga AM, Ostroveanu A, Luiten PG, Schmidt M, Eisel UL (2008) Neuronal AKAP150 coordinates PKA and Epac-mediated PKB/Akt phosphorylation. *Cell Signal* 20:1715–1724
- Oestreich EA, Wang H, Malik S, Kaproth-Joslin KA, Blaxall BC, Kelley GG, Dirksen RT, Smrcka AV (2007) Epac-mediated activation of phospholipase C ϵ plays a critical role in β -adrenergic receptor-dependent enhancement of Ca²⁺ mobilization in cardiac myocytes. *J Biol Chem* 282:5488–5495
- Oestreich EA, Malik S, Goonasekera SA, Blaxall BC, Kelley GG, Dirksen RT, Smrcka AV (2009) Epac and phospholipase C ϵ regulate Ca²⁺ release in the heart by activation of protein kinase C ϵ and calcium-calmodulin kinase II. *J Biol Chem* 284:1514–1522
- Ørskov C, Holst JJ, Nielsen OV (1988) Effect of truncated glucagon-like peptide-1 [proglucagon-(78–107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. *Endocrinology* 123:2009–2013
- Overton HA, Fyfe MC, Reynet C (2008) GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity. *Br J Pharmacol* 153(Suppl 1):S76–S81
- Ozaki N, Shibasaki T, Kashima Y, Miki T, Takahashi K, Ueno H, Sunaga Y, Yano H, Matsuura Y, Iwanaga T, Takai Y, Seino S (2000) cAMP-GEFII is a direct target of cAMP in regulated exocytosis. *Nat Cell Biol* 2:805–811
- Park S, Dong X, Fisher TL, Dunn S, Omer AK, Weir G, White MF (2006) Exendin-4 uses Irs2 signaling to mediate pancreatic β cell growth and function. *J Biol Chem* 281:1159–1168
- Park JH, Kim SJ, Park SH, Son DG, Bae JH, Kim HK, Han J, Song DK (2012) Glucagon-like peptide-1 enhances glucokinase activity in pancreatic β -cells through the association of Epac2 with Rim2 and Rab3A. *Endocrinology* 153:574–582
- Patti ME, Corvera S (2010) The role of mitochondria in the pathogenesis of type 2 diabetes. *Endocr Rev* 31:364–395
- Pereira L, Cheng H, Lao DH, Na L, van Oort RJ, Brown JH, Wehrens XH, Chen J, Bers DM (2013) Epac2 mediates cardiac β 1-adrenergic-dependent sarcoplasmic reticulum Ca²⁺ leak and arrhythmia. *Circulation* 127:913–922
- Petyuk VA, Qian WJ, Hinault C, Gritsenko MA, Singhal M, Monroe ME, Camp DG 2nd, Kulkarni RN, Smith RD (2008) Characterization of the mouse pancreatic islet proteome and comparative analysis with other mouse tissues. *J Proteome Res* 7:3114–3126
- Peyot ML, Gray JP, Lamontagne J, Smith PJ, Holz GG, Madiraju SR, Prentki M, Heart E (2009) Glucagon-like peptide-1 induced signaling and insulin secretion do not drive fuel and energy metabolism in primary rodent pancreatic β -cells. *PLoS One* 4:e6221
- Prentki M, Matschinsky FM (1987) Ca²⁺, cAMP, and phospholipid-derived messengers in coupling mechanisms of insulin secretion. *Physiol Rev* 67:1185–1248
- Pyne NJ, Furman BL (2003) Cyclic nucleotide phosphodiesterases in pancreatic islets. *Diabetologia* 46:1179–1189
- Quoyer J, Longuet C, Broca C, Linck N, Costes S, Varin E, Brockaert J, Bertrand G, Dalle S (2010) GLP-1 mediates antiapoptotic effect by phosphorylating Bad through a β arrestin 1-mediated ERK1/2 activation in pancreatic β -cells. *J Biol Chem* 285:1989–2002
- Ramos LS, Zippin JH, Kamenetsky M, Buck J, Levin LR (2008) Glucose and GLP-1 stimulate cAMP production via distinct adenylyl cyclases in INS-1E insulinoma cells. *J Gen Physiol* 132:329–338
- Rehmann H (2012) Epac2: a sulfonylurea receptor? *Biochem Soc Trans* 40:6–10
- Renström E, Eliasson L, Rorsman P (1997) Protein kinase A-dependent and independent stimulation of exocytosis by cAMP in mouse pancreatic β -cells. *J Physiol* 502:105–118
- Roger B, Papin J, Vacher P, Raoux M, Mulot A, Dubois M, Kerr-Conte J, Voy BH, Pattou F, Charpentier G, Jonas JC, Moustaid-Moussa N, Lang J (2011) Adenylyl cyclase 8 is central to glucagon-like peptide 1 signalling and effects of chronically elevated glucose in rat and human pancreatic β cells. *Diabetologia* 54:390–402
- Scott JD, Santana LF (2010) A-kinase anchoring proteins: getting to the heart of the matter. *Circulation* 121:1264–1271

- Seino S, Shibasaki T (2005) PKA-dependent and PKA-independent pathways for cAMP-regulated exocytosis. *Physiol Rev* 85:1303–1342
- Seino S, Takahashi H, Fujimoto W, Shibasaki T (2009) Roles of cAMP signalling in insulin granule exocytosis. *Diabetes Obes Metab* 11(Suppl 4):180–188
- Seino S, Shibasaki T, Minami K (2011) Dynamics of insulin secretion and the clinical implications for obesity and diabetes. *J Clin Invest* 121:2118–2125
- Shah U, Kowalski TJ (2010) GPR119 agonists for the potential treatment of type 2 diabetes and related metabolic disorders. *Vitam Horm* 84:415–448
- Shao W, Yu Z, Fantus IG, Jin T (2010) Cyclic AMP signaling stimulates proteasome degradation of thioredoxin interacting protein (TxNIP) in pancreatic β -cells. *Cell Signal* 22:1240–1246
- Shao W, Wang Z, Ip W, Chiang YT, Xiong X, Chai T, Xu C, Wang Q, Jin T (2013) GLP-1(28–36) improves β -cell mass and glucose disposal in streptozotocin induced diabetes mice and activates PKA- β -catenin signaling in β -cells in vitro. *Am J Physiol Endocrinol Metab* 304: E1263–E1272
- Sharp GW (1996) Mechanisms of inhibition of insulin release. *Am J Physiol* 271:C1781–C1799
- Shibasaki T, Sunaga Y, Seino S (2004) Integration of ATP, cAMP, and Ca^{2+} signals in insulin granule exocytosis. *Diabetes* 53(Suppl 3):S59–S62
- Shibasaki T, Takahashi H, Miki T, Sunaga Y, Matsumura K, Yamanaka M, Zhang C, Tamamoto A, Satoh T, Miyazaki J, Seino S (2007) Essential role of Epac2/Rap1 signaling in regulation of insulin granule dynamics by cAMP. *Proc Natl Acad Sci USA* 104:19333–19338
- Shiota C, Larsson O, Shelton KD, Shiota M, Efanov AM, Hoy M, Lindner J, Kooptiwut S, Juntti-Berggren L, Gromada J, Berggren PO, Magnuson MA (2002) Sulfonylurea receptor type 1 knock-out mice have intact feeding-stimulated insulin secretion despite marked impairment in their response to glucose. *J Biol Chem* 277:37176–37183
- Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB (2013) Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. *JAMA Intern Med* 173:534–539
- Skelin M, Rupnik M (2011) cAMP increases the sensitivity of exocytosis to Ca^{2+} primary through protein kinase A in mouse pancreatic β cells. *Cell Calcium* 49:89–99
- Skoglund G, Hussain MA, Holz GG (2000) Glucagon-like peptide 1 stimulates insulin gene promoter activity by protein kinase A-independent activation of the rat insulin I gene cAMP response element. *Diabetes* 49:1156–1164
- Smrcka AV, Brown JH, Holz GG (2012) Role of phospholipase C ϵ in physiological phosphoinositide signaling networks. *Cell Signal* 24:1333–1343
- Soga T, Ohishi T, Matsui T, Saito T, Matsumoto M, Takasaki J, Kamohara M, Hiyama H, Yoshida S, Momose K, Ueda Y, Matsushime H, Kobori M, Furuichi K (2005) Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor. *Biochem Biophys Res Commun* 326:744–751
- Song WJ, Schreiber WE, Zhong E, Liu FF, Kornfeld BD, Wondisford FE, Hussain MA (2008) Exendin-4 stimulation of cyclin A2 in β -cell proliferation. *Diabetes* 57:2371–2381
- Song WJ, Seshadri M, Ashraf U, Mdluli T, Mondal P, Keil M, Azevedo M, Kirschner LS, Stratakis CA, Hussain MA (2011) Snapin mediates incretin action and augments glucose-dependent insulin secretion. *Cell Metab* 13:308–319
- Song WJ, Mondal P, Li Y, Lee SE, Hussain MA (2013) Pancreatic β -cell response to increased metabolic demand and to pharmacologic secretagogues requires EPAC2A. *Diabetes* 62:2796–2807
- Sonoda N, Imamura T, Yoshizaki T, Babendure JL, Lu JC, Olefsky JM (2008) β -arrestin-1 mediates glucagon-like peptide-1 signaling to insulin secretion in cultured pancreatic β cells. *Proc Natl Acad Sci USA* 105:6614–6619
- Straub SG, Sharp GW (2012) Evolving insights regarding mechanisms for the inhibition of insulin release by norepinephrine and heterotrimeric G proteins. *Am J Physiol Cell Physiol* 302: C1687–C1698

- Suga S, Kanno T, Ogawa Y, Takeo T, Kamimura N, Wakui M (2000) cAMP-independent decrease of ATP-sensitive K^+ channel activity by GLP-1 in rat pancreatic β -cells. *Pflugers Arch* 440:566–572
- Takahashi N, Kadowaki T, Yazaki Y, Ellis-Davies GC, Miyashita Y, Kasai H (1999) Post-priming actions of ATP on Ca^{2+} -dependent exocytosis in pancreatic β cells. *Proc Natl Acad Sci USA* 96:760–765
- Takeda Y, Amano A, Noma A, Nakamura Y, Fujimoto S, Inagaki N (2011) Systems analysis of GLP-1 receptor signaling in pancreatic β -cells. *Am J Physiol Cell Physiol* 301: C792–C803
- Talbot J, Joly E, Prentki M, Buteau J (2012) β -arrestin 1-mediated recruitment of c-Src underlies the proliferative action of glucagon-like peptide-1 in pancreatic β INS832/13 cells. *Mol Cell Endocrinol* 364:65–70
- Tarasov AI, Semplici F, Li D, Rizzuto R, Ravier MA, Gilon P, Rutter GA (2013) Frequency-dependent mitochondrial Ca^{2+} accumulation regulates ATP synthesis in pancreatic β -cells. *Pflugers Arch* 465:543–554
- Taylor SS, Kim C, Cheng CY, Brown SH, Wu J, Kannan N (2008) Signaling through cAMP and cAMP-dependent protein kinase: diverse strategies for drug design. *Biochim Biophys Acta* 1784:16–26
- Tengholm A (2012) Cyclic AMP dynamics in the pancreatic β -cell. *Ups J Med Sci* 117:365–369
- Thams P, Anwar MR, Capito K (2005) Glucose triggers protein kinase A-dependent insulin secretion in mouse pancreatic islets through activation of the K-ATP channel-dependent pathway. *Eur J Endocrinol* 152:671–677
- Thorens B (1992) Expression cloning of the pancreatic β cell receptor for the gluco-incretin hormone glucagon-like peptide 1. *Proc Natl Acad Sci USA* 89:8641–8645
- Tian G, Sandler S, Gylfe E, Tengholm A (2011) Glucose- and hormone-induced cAMP oscillations in α - and β -cells within intact pancreatic islets. *Diabetes* 60:1535–1543
- Tian G, Tepikin AV, Tengholm A, Gylfe E (2012) cAMP induces stromal interaction molecule 1 (STIM1) puncta but neither Orai1 protein clustering nor store-operated Ca^{2+} entry (SOCE) in islet cells. *J Biol Chem* 287:9862–9872
- Tourrel C, Bailbe D, Meile MJ, Kergoat M, Portha B (2001) Glucagon-like peptide-1 and exendin-4 stimulate β -cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. *Diabetes* 50:1562–1570
- Tsalkova T, Gribenko AV, Cheng X (2011) Exchange protein directly activated by cyclic AMP isoform 2 is not a direct target of sulfonylurea drugs. *Assay Drug Dev Technol* 9:88–91
- Tsalkova T, Mei FC, Li S, Chepurny OG, Leech CA, Liu T, Holz GG, Woods VL, Cheng X (2012) Isoform-specific antagonists of exchange proteins directly activated by cAMP. *Proc Natl Acad Sci USA* 109:18613–18618
- Tschen SI, Georgia S, Dhawan S, Bhushan A (2011) Skp2 is required for incretin hormone-mediated β -cell proliferation. *Mol Endocrinol* 25:2134–2143
- Tsuboi T, da Silva Xavier G, Holz GG, Jouaville LS, Thomas AP, Rutter GA (2003) Glucagon-like peptide-1 mobilizes intracellular Ca^{2+} and stimulates mitochondrial ATP synthesis in pancreatic MIN6 β -cells. *Biochem J* 369:287–299
- Vikman J, Svensson H, Huang YC, Kang Y, Andersson SA, Gaisano HY, Eliasson L (2009) Truncation of SNAP-25 reduces the stimulatory action of cAMP on rapid exocytosis in insulin-secreting cells. *Am J Physiol Endocrinol Metab* 297:E452–E461
- Vliem MJ, Ponsioen B, Schwede F, Pannekoek WJ, Riedl J, Jalink K, Genieser HG, Bos JL, Rehmann H (2008) 8-pCPT-2'-O-Me-cAMP-AM: an improved Epac-selective cAMP analogue. *Chembiochem* 9:2052–2054
- Wan QF, Dong Y, Yang H, Lou X, Ding J, Xu T (2004) Protein kinase activation increases insulin secretion by sensitizing the secretory machinery to Ca^{2+} . *J Gen Physiol* 124: 653–662

- Wang X, Zhou J, Doyle ME, Egan JM (2001) Glucagon-like peptide-1 causes pancreatic duodenal homeobox-1 protein translocation from the cytoplasm to the nucleus of pancreatic β -cells by a cyclic adenosine monophosphate/protein kinase A-dependent mechanism. *Endocrinology* 142:1820–1827
- Wang Q, Li L, Xu E, Wong V, Rhodes C, Brubaker PL (2004) Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-1 β cells. *Diabetologia* 47:478–487
- Welch EJ, Jones BW, Scott JD (2010) Networking with AKAPs: context-dependent regulation of anchored enzymes. *Mol Interv* 10:86–97
- Wice BM, Wang S, Crimmins DL, Diggs-Anrews KA, Althage MC, Ford EL, Tran H, Ohlendorf M, Griest TA, Wang Q, Fisher SJ, Ladenson JH, Polonsky KS (2010) Xenin-25 potentiates glucose-dependent insulinotropic polypeptide action via a novel cholinergic relay mechanism. *J Biol Chem* 285:19842–19853
- Wice BM, Reeds DN, Tran H, Crimmins DL, Patterson BW, Dunai J, Wallendorf MJ, Ladenson JH, Villareal DT, Polonsky KS (2012) Xenin-25 amplifies GIP-mediated insulin secretion in humans with normal and impaired glucose tolerance but not type 2 diabetes. *Diabetes* 61:1793–1800
- Wiederkehr A, Wollheim CB (2008) Impact of mitochondrial calcium on the coupling of metabolism to insulin secretion in the pancreatic β -cell. *Cell Calcium* 44:64–76
- Winzell MS, Ahrén B (2004) The high-fat diet-fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes. *Diabetes* 53(Suppl 3):S215–S219
- Winzell MS, Ahrén B (2007) G-protein-coupled receptors and islet functions – implications for treatment of type 2 diabetes. *Pharmacol Ther* 116:437–448
- Xu G, Stoffers DA, Habener JF, Bonner-Weir S (1999) Exendin-4 stimulates both β -cell replication and neogenesis, resulting in increased β -cell mass and improved glucose tolerance in diabetic rats. *Diabetes* 48:2270–2276
- Yada T, Itoh K, Nakata M (1993) Glucagon-like peptide-1-(7–36)amide and a rise in cyclic adenosine 3',5'-monophosphate increase cytosolic free Ca^{2+} in rat pancreatic β -cells by enhancing Ca^{2+} channel activity. *Endocrinology* 133:1685–1692
- Yaekura K, Yada T (1998) $[Ca^{2+}]_i$ -reducing action of cAMP in rat pancreatic β -cells: involvement of thapsigargin-sensitive stores. *Am J Physiol* 274(Cell Physiol 43):C513–C521
- Yang Y, Gillis KD (2004) A highly Ca^{2+} -sensitive pool of granules is regulated by glucose and protein kinases in insulin-secreting INS-1 cells. *J Gen Physiol* 124:641–651
- Yang Y, Craig TJ, Chen X, Ciuffo LF, Takahashi M, Morgan A, Gillis KD (2007) Phosphomimetic mutation of Ser-187 of SNAP-25 increases both syntaxin binding and highly Ca^{2+} -sensitive exocytosis. *J Gen Physiol* 129:233–244
- Yang Y, Shu X, Liu D, Shang Y, Wu Y, Pei L, Xu X, Tian Q, Zhang J, Qian K, Wang YX, Petralia RS, Tu W, Zhu LQ, Wang JZ, Lu Y (2012) EPAC null mutation impairs learning and social interactions via aberrant regulation of miR-124 and Zif268 translation. *Neuron* 73:774–788
- Yi P, Park JC, Melton DA (2013) Betatrophin: a hormone that controls pancreatic β cell proliferation. *Cell* 153:747–758
- Ying Y, Li L, Cao W, Yan D, Zeng Q, Kong X, Lu L, Yan M, Xu X, Qu J, Su Q, Ma X (2012) The microtubule associated protein syntabulin is required for glucose-stimulated and cAMP-potentiated insulin secretion. *FEBS Lett* 586:3674–3680
- Yoshida M, Yamato S, Dezaki K, Nakata M, Kawakami M, Yada T, Kakei M (2012) Activation of nonselective cation channels via cAMP-EPAC2 pathway is involved in exendin-4 potentiated insulin secretion. European Association for the Study of Diabetes (EASD), annual meeting, Berlin. Abstract #488
- Yusta B, Baggio LL, Estall JL, Koehler JA, Holland DP, Li H, Pipeleers D, Ling Z, Drucker DJ (2006) GLP-1 receptor activation improves β cell function and survival following induction of endoplasmic reticulum stress. *Cell Metab* 4:391–406

- Zhang CL, Katoh M, Shibasaki T, Minami K, Sunaga Y, Takahashi H, Yokoi N, Iwasaki M, Miki T, Seino S (2009) The cAMP sensor Epac2 is a direct target of antidiabetic sulfonylurea drugs. *Science* 325:607–610
- Zhao AZ, Bornfeldt KE, Beavo JA (1998) Leptin inhibits insulin secretion by activation of phosphodiesterase 3B. *J Clin Invest* 102:869–873
- Zippin JH, Chen Y, Straub SG, Hess KC, Diaz A, Lee D, Tso P, Holz GG, Sharp GW, Levin LR, Buck J (2013) $\text{CO}_2/\text{HCO}_3^-$ and calcium regulated soluble adenylyl cyclase as a physiological ATP sensor. *J Biol Chem* 288:33283–33291